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Abstract
LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY FOR THE STUDY OF ARACHIDONIC
ACID METABOLITES
Xiaojing Liu
Ian A. Blair, PhD
Arachidonic acid (AA) oxidation metabolism has been an important research topic for decades, and
numerous oxidation products as well as enzymes involved in AA metabolism together with their downstream
metabolites have been identified, although unknown pathways still remain to be characterized. In the present a
study a new AA metabolite, 11-oxo-eicosatetraenoic acid (ETE), generated from a major product of
cyclooxygenase (COX-2), 11(R)-hydroxyeicosatetraenoic acid (HETE), through 15-hydroxyprostaglandine
dehydrogenase (15-PGDH)-mediated oxidation. 11-Oxo-ETE was found to have an anti-proliferative effect
on human umbilical vein endothelial cells (HUVECs), with a similar IC50 to a well- known anti-
inflammatory mediator, 15-deoxy-12,14-prostaglandin J2 (15d-PGJ2). It was also found that 11-oxo-ETE
could be inactivated through the glutathione-S-transferase (GST)/glutathione (GSH) pathway by forming a
GSH adduct, or by undergoing reduction to 11(S)-HETE through metabolism by unknown reductases.
AA is also subject to non-enzymatic oxidation due to its bis-allylic hydrogen atoms and four double bonds.
Chiral LC-MS methods were used to distinguish the enzymatic and non-enzymatic products by monitoring
the relevant products that were formed. Non-enzymatic pathways generate racemic mixtures, while enzymatic
pathways are normally highly stereoselective. It is known that both enzymatic and non-enzymatic oxidation of
AA followed by decomposition of the resulting oxidized intermediates, can generates short-chain aldehydes
such as 4-hydroperoxy-2(E)-nonenal (HPNE), 4-hydroxy-2(E) nonenal (HNE), and 4-oxo-2(E)-nonenal
(ONE). However, it was discovered that the endoperoxide product of COX-2, PGG2, is a major contributor
to the formation of these aldehydes. Moreover, PGG2 and other hydroperoxides generate HPNE or HNE
with different chiral characteristics. From COX-2 expressing human colorectal adenocarcinoma epithelial cell
line (LoVo) cell lysate, 4(S)-HNE was detected with high enantiomeric purity indicating that the primary
source was prostaglandin G2 (PGG2) and not 15- hydroperoxyeicosatetraenoic acid (HPETE) as had been
previously suggested.
Finally, through studies of 11(R)-HPETE and 15-HPETE decomposition, a new carboxylate-containing
aldehyde, 11-oxoundeca-5,8-dienoic acid (OUDE) was identified. OUDE contains the -terminus of the lipid
hydroperoxide precursor and is analogous to HNE, which is derived from the -terminus. Nuclear magnetic
resonance spectroscopy (NMR) together with chiral liquid chromatography-mass spectrometry (LC-MS)
analysis showed that OUDE was a mixture of two double bond isomers. It has been proposed that the two
isomers are generated as a result of a rearrangement reaction subsequent to the formation of OUDE. In
addition, , by monitoring the chirality of the HNE that was formed from 11(R)-HPETE and 15-HPETE
decomposition, a homolytic mechanism for HNE formation has been proposed.
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Abstract 
LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY FOR THE STUDY 
OF ARACHIDONIC ACID METABOLITES  
Xiaojing Liu 
Ian A. Blair, PhD 
Arachidonic acid (AA) oxidation metabolism has been an important research 
topic for decades, and numerous oxidation products as well as enzymes 
involved in AA metabolism together with their downstream metabolites have 
been identified, although unknown pathways still remain to be characterized. 
In the present a study a new AA metabolite, 11-oxo-eicosatetraenoic acid 
(ETE), generated from a major product of cyclooxygenase (COX-2), 11(R)-
hydroxyeicosatetraenoic acid (HETE), through 15-hydroxyprostaglandine 
dehydrogenase (15-PGDH)-mediated oxidation. 11-Oxo-ETE was found to 
have an anti-proliferative effect on human umbilical vein endothelial cells 
(HUVECs), with a similar IC50 to a well- known anti-inflammatory mediator, 
15-deoxy-12,14-prostaglandin J2 (15d-PGJ2). It was also found that 11-oxo-
ETE could be inactivated through the glutathione-S-transferase 
(GST)/glutathione (GSH) pathway by forming a GSH adduct, or by 
undergoing reduction to 11(S)-HETE through metabolism by unknown 
reductases. 
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AA is also subject to non-enzymatic oxidation due to its bis-allylic hydrogen 
atoms and four double bonds. Chiral LC-MS methods were used to distinguish 
the enzymatic and non-enzymatic products by monitoring the relevant 
products that were formed. Non-enzymatic pathways generate racemic 
mixtures, while enzymatic pathways are normally highly stereoselective.  It 
is known that both enzymatic and non-enzymatic oxidation of AA followed by 
decomposition of the resulting oxidized intermediates, can generates short-
chain aldehydes such as 4-hydroperoxy-2(E)-nonenal (HPNE), 4-hydroxy-2(E) 
nonenal (HNE), and 4-oxo-2(E)-nonenal (ONE).  However, it was discovered 
that the endoperoxide product of COX-2, PGG2, is a major contributor to the 
formation of these aldehydes. Moreover, PGG2 and other hydroperoxides 
generate HPNE or HNE with different chiral characteristics. From COX-2 
expressing human colorectal adenocarcinoma epithelial cell line (LoVo) cell 
lysate, 4(S)-HNE was detected with high enantiomeric purity indicating that 
the primary source was prostaglandin G2 (PGG2) and not 15- 
hydroperoxyeicosatetraenoic acid (HPETE) as had been previously suggested. 
Finally, through studies of 11(R)-HPETE and 15-HPETE decomposition, a new 
carboxylate-containing aldehyde, 11-oxoundeca-5,8-dienoic acid (OUDE) was 
identified. OUDE contains the –terminus of the lipid hydroperoxide precursor 
and is analogous to HNE, which is derived from the –terminus.  Nuclear 
magnetic resonance spectroscopy (NMR) together with chiral liquid 
chromatography-mass spectrometry (LC-MS) analysis showed that OUDE 
was a mixture of two double bond isomers. It has been proposed that the 
two isomers are generated as a result of a rearrangement reaction 
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subsequent to the formation of OUDE. In addition, , by monitoring the 
chirality of the HNE that was formed from 11(R)-HPETE and 15-HPETE 
decomposition, a homolytic mechanism for HNE formation has been proposed. 
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1 
Chapter 1  General Introduction 
1.1  Lipid classification  
1.1.1 Lipid classification by function 
Lipids can be classified by their functions into storage lipids, structural lipids 
(membrane lipids), hormones, and vitamins. Storage lipids exist in the form 
of triacylglycerols, while structural lipids usually contain a polar head and a 
long carbon chain tail. Based on the polar head and carbon chain 
compositions, membrane lipids can be further classified into different 
categories. Hormones and vitamins represent only a small component of 
cellular lipids when compared with storage and structural lipids, but they play 
important roles in regulating biological process. Fatty acids which are major 
components of lipids, can be classified as saturated and unsaturated based 
on the presence or absence of double bonds. Polyunsaturated fatty acids 
(PUFAs) are subject to oxidation by chemical oxidants or enzymes and the 
resulting oxidation products can function as “hormone-like” signaling 
molecules. 
1.1.2 Phospholipids  
Phospholipids are major components of all cell membranes where they form 
lipid bilayers. Most phospholipids contain a diglyceride, a phosphate group, 
and a polar head group such as choline. However, sphingolipids, which 
represent a major class of phospholipid, contain a sphingosine moiety instead 
of glycerol. The structure of a typical glycerophospholipid, sn1-stearoyl-2-
arachidonoyl-phosphatidylinositol is shown in Figure 1.1. Glycerol forms an 
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ester bond with the carboxylic acid group of stearic acid at the sn-1 position, 
and the other ester bond at the sn-2 position is formed with arachidonic acid. 
At-the sn-3 position, there is a polar phosphoinositol head group. As 
illustrated in Figure 1.1, the arachidonyl substituent has 4 double bonds, 
while the stearoyl substituent is fully saturated. In addition to arachidonic 
acid, there are numerous other unsaturated and polyunsaturated fatty acids. 
These fatty acids are classified as -9, -6 or -3, depending on the position 
of the last double bond. For example, arachidonic acid (AA) has a double 
bond at C14-C15, and the terminal carbon is at C-20, which is designated as 
-1. Therefore, the first double bond is at -6.   
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Figure 1.1. Structures of unsaturated fatty acids and sn-1-stearoyl-2-
arachidonoyl phosphatidylinositol.  
 
AA has 20 carbon atoms and 4 double bonds, so it can also be abbreviated as 
20:4-6 or 20:4n-6. Similarly, docosahexaenoic acid (common name: DHA) 
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has 22 carbons and 6 double bonds, and the last double bond is at C19-C20, 
so it’s abbreviated as  22:6-3 or 22:6n-3. 
Unsaturated fatty acids with more than three double bonds are frequently 
seen in animals, while in plants there are usually less than three. The trans-
double bonds allow them to be less tightly packed than saturated fatty acids, 
so membranes containing unsaturated fatty acids have some degree of 
fluidity. Moreover, compared to saturated fatty acids, the unsaturated fatty 
acids are much more readily oxidized, and the corresponding oxidation 
products are important biological signal mediators. When there is more than 
one double bond, there is usually a methylene group connecting the two 
double bonds, which is also known as a bis-allylic configuration. The 
abstraction of a bis-allylic hydrogen atom is an important step in lipid 
peroxidation and in enzymatic oxidation.   
1.2   Arachidonic acid metabolism 
 
1.2.1 The importance of arachidonic acid 
There have been numerous studies on AA metabolism because it is the 
precursor of a diverse biologically active family of biologically active lipid 
mediators known as eicosanoids (1). They have multiple functions in 
inflammation, cancer or immunity through modulating signaling pathways, 
transcription factor activity and gene expression. The eicosanoids derived 
from arachidonic acid are called -6 eicosanoids and are often pro-
inflammatory either as G-protein coupled receptor (GPCR) agonists or as 
nuclear transcription factor ligands (2,3,4,5). 
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1.2.2 Overview of AA metabolism 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Simplified scheme of AA metabolism. R1: stearoyl (18:0); 
DAG: Diacylglycerol; DAGL: DAG lipase; PI: Phosphatidylinositol; PLA2: 
phospholipase A2; PLC: Phospholipase C; AEA: Arachidonoylethanolamide 
(anandamide); FAAH: Fatty acid amide hydrolase; AA: arachidonic acid 
 
AA in mammals mainly exists as an esterified form in acylglycerides, and 
phospholipids. Generally, before esterified AA can be converted to 
eicosanoids, it has to be released as a free fatty acid. For example, as shown 
in Figure 1.2, esterified arachidonic acid at the sn-2 position on 
phosphatidylinosotol can be directly released by the phospholipase A2 (PLA2) 
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enzyme (6). Alternatively, Phospholipase C (PLC)-mediated hydrolysis of 
phospholipids can first occur at the sn-3 position, in which case the polar 
phosphoinositol head group is removed, forming a diacylglycerol (DAG). Then 
DAG is further metabolized by DAG lipase (DAGL) to release free arachidonic 
acid. There are also additional sources of free arachidonic acid (7,8). For 
example, arachidonylethanolamide (anandamide, AEA) is an endogenous 
cannabinoid neurotransmitter. It is the substrate for enzyme fatty acid amide 
hydrolase (FAAH), which converts AEA into ethanolamine and arachidonic 
acid. In most of the tissues, the PLA2 and PLC pathways play the major role, 
while recent research has shown that in brain, the FAAH pathway are more 
important than the other two (8).  
Besides enzymatic pathways, AA is also subject to autoxidation both in vitro 
and in vivo. Since arachidonic acid has four double bonds, and three bis-
allylic hydrogen atoms, when it is exposed to air or free radicals, or when it is 
heated, it is readily oxidized (9). Although the intracellular environment is 
mostly reducing, within mitochondria there is a pool of free radicals, which 
could attack AA, and initiate autoxidation. Autoxidation products are different 
from enzymatic products in that they are racemic rather than 
enantiomerically pure metabolites observed from enzymatic reactions. Thus, 
although hydroperoxyeicosatetraenoic acids (HPETEs) can be generated both 
from enzymatic and non-enzymatic arachidonic acid oxidation, a chiral 
analysis can distinguish the two pathways. Furthermore, autoxidation occurs 
with little regioselectivity, which leads to a myriad of products. Thus, the 
initially formed HPETEs undergo further oxidation to generate a family of 
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eicosanoids known as isoprostanes (10). Several of the isoprostanes have 
been widely used as biomarkers of oxidative stress (11,12). AA-derived -6 
eicosanoids are mostly pro-inflammatory, while -3-derived eicosanoids are 
much less inflammatory. It has been proposed that -3 eicosapentaenoic 
acid has some health benefits because it can compete with AA as the 
substrate of related enzymes to lower the formation of inflammatory 
eicosanoids (13,14).   
 
1.3    COX-2 pathway 
1.3.1 COX structure and catalytic mechanism 
 
 
Figure 1.3 Crystal structures of ovine COX-1 (left) and murine COX-2 
(right) homodimers by Browner and Kurumbail. The red color 
represents the catalytic cofactor, heme, the blue area is the dimerization 
domain, and the yellow color is membrane binding domain. The peroxidase 
active site is on the top cleft of each monomer. This figure is modified from 
(15). 
 
Cyclooxygenase (COX) is a membrane protein located on the inner and outer 
membrane of nuclear envelope, and the surface of the endoplasmic reticulum 
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lumen. It has dual catalytic functions. There are both cyclooxygenase and 
peroxidase (POX) active sites in one enzyme. The cyclooxygenase site 
converts AA into PGG2 and HPETEs, while the peroxidase site reduces the 
hydroperoxide groups in PGG2 or HPETEs to the corresponding hydroxyl 
groups. As shown in Figure 1.3, the red color represents the cofactor heme, 
while the open cleft on top of each monomer is the POX site. The COX and 
POX activities are functionally interdependent. As shown in Figure 1.4, it has 
been generally accepted that there is a protein radical formed during the 
catalytic process. Alkyl hydroperoxides bind to heme in the POX site, and are 
reduced to the corresponding alkyl hydroxyl, and meanwhile the resting 
heme is oxidized to the oxyferryl form and a protoporphyrin radical cation 
(Fe4+=O.) is formed. This intermediate is so unstable that it attacks the 
neighboring tyrosine residue (385Tyr), and abstracts hydrogen from the 385Tyr 
side chain, resulting in the formation of 385Tyr radical and oxyferryl Fe4+=O. 
The 385Tyr radical then abstracts pro-S hydrogen at C13 of arachidonic acid, 
which binds to COX active site. Then 385Tyr is recycled, while the radical is 
transferred to AA. The C11-C12 double bond then relocates to C12-C13 and 
forms a conjugate double bond with C14-C15, the C13 radical is also 
transferred to C11. Then oxygen is inserted at the C11 position and the 
radical is transferred to oxygen, which rapidly attacks C8-C9 double bond, 
and form a dioxygen (endoperoxide) bridge between C11 and C9, together 
with a C8 radical. This is then followed by a C8 radical attraction of C12-C13 
double bond and formation of C8-C12 single bond, together with a C13 
radical. After translocation of C13 radical and C14-C15 double bond, C15 is 
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formed and followed by oxygen attachment. Finally this PGG2 precursor 
abstracts a hydrogen atom from neighboring reducing environment and 
forms the final PGG2. PGG2 will function as alkyl hydroperoxide and enter the 
peroxidase site, where it is reduced to PGH2. Usually after several cycles, the 
COX will lose it is activity, which is called COX suicide. The exact mechanism 
is not clear yet, but there are reports showing it may be related with the 
quench of tyrosine radicals or damage to COX protein by free radicals, and 
the addition of phenol slows the inactivation process (16,17).  
1.3.2 COX isoenzymes and diseases 
Before 1991, only one COX was identified, and then after that, an inducible 
COX isoenzyme was described by three independent groups (18,19,20). 
Simmons and Herschman (19, 20) together with their colleagues found 
mRNAs whose expression was induced in chicken and mouse fibroblasts in 
response to src and tumor-promoting phorbol esters. Later, they found these 
mRNAs encoded proteins shared 60% amino acid sequence with the earlier 
COX mRNA, but their expression and their biological activity were quite 
different. Thus, it is concluded that COX has two isoenzymes, COX-1 and 
COX-2. COX-1 is constitutively expressed in many cells, while COX-2 is 
induced in response to cytokines, hormones, growth factors, bacteria 
endotoxin, and certain other stimuli. Thus, COX-2 is usually over-expressed 
in inflammatory tissues or tumors. COX-1 functions as a house-keeping 
enzyme and its products help to maintain normal biological processes. 
However, COX-2 is related with many diseases, including inflammatory 
disorders, cancer, diabetes, and so on. Over-expression of COX-2 contributes 
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to accumulation of prostaglandins, which are usually pro-inflammatory, as 
described previously, although it was also reported that certain COX-2 
mediated -3  fatty acids metabolites are anti-inflammatory (21).  
1.3.3 COX inhibitors 
COX is a target for developing anti-inflammatory drugs, known as non-
steroidal anti-inflammatory drugs (NSAIDs). Within the NSAIDs, aspirin was 
the earliest developed. It also differs from other NSAIDs, in that it converts 
COX-2 into a 15(R)-lipoxygenase (LOX), instead of completely inhibiting 
COX-2 activity. It is also the only NSAID which covalently modifies COX-1 
and COX-2, while other NSAIDs are usually competitive substrates of COX. 
Aspirin completely inhibits both COX-1 activity, and switches COX-2 to a 
15(R)-LOX, so PG synthesis is inhibited, and it has many side effects, such as 
a pro-aggregatory effect due to inhibition of platelet COX-1-mediated 
thromboxane A2 biosynthesis. Aspirin also causes irritation of the gastric 
mucosa due to inhibition of PG synthesis. In order to overcome this effect, 
COX-2 specific inhibitors have been developed, although they have significant 
adverse cardiovascular effects (22).  
It is known that among the NSAIDs, aspirin is the most effective anti-platelet 
drug, because it can covalently modify COX-1, and more efficiently inhibit the 
biosynthesis of pro-aggregatory thromboxane A2 (23). Moreover, there are 
studies showing that daily doses of aspirin might help to reduce cancer risk 
(24,25) .  
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The mechanism through which aspirin functions as a chemoprevention agent 
is still not quite clear yet, and no evidence shows whether a COX is involved 
or not. Thus, more studies are needed to address these issues and to 
develop safer chemoprevention candidates. 
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Figure 1.4. The mechanism of cyclooxygenase and peroxidase 
activity of COX. This figure is modified from (15). 
 
1.4   15-PGDH pathway 
1.4.1 15-PGDH structure and function 
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Figure 1.5:  Crystal structure of 15-PGDH. Figure 1.5a. the crystal 
structure of 15-PGDH with NAD+ and PGE2 complex. Figure 1.5b. the 
catalytic sites. Bottom, the chemical structures of PGE2 and dehydrated 
product 15-keto-PGE2. Figure 1.5a and 1.5b are modified from ref (26) 
 
The eicosanoids generated from COXs are not metabolically stable. Thus, the 
overall eicosanoid levels are controlled both by COXs and by eicosanoid 
catabolism enzymes.  Among the eicosanoid catabolism enzymes, 15-
hydroxyprostaglandin dehydrogenase (15-PGDH) has been studied 
intensively. 15-PGDH is an enzyme which converts the (S)-hydroxyl group at 
carbon 15 on eicosanoids to a keto group. For example, PGE2 undergoes 15-
PGDH-mediated conversion to the biologically inactive 15-keto-PGE2 (Figure 
1.5, which can be further metabolized to 13,14-dihydro-15-keto-PGE2 by a 
specific reductase. 15-PGDH primarily uses NAD+ as its cofactor. Although 
there is a type II 15-PGDH which uses NADP+ as its cofactor, type II 15-
PGDH has a Km value toward PGE2 which is two orders of magnitude higher 
than NAD+ dependent 15-PGDH (27). In addition to being reduced, 15-keto-
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PGE2 can undergo glutathione S-transferase (GST)-mediated conjugation 
with glutathione (GSH). Other eicosanoids containing a 15(S)-hydroxyl group 
can undergo a similar route of catabolism. The GSH conjugates have higher 
polarity than their precursors, and they can be excreted out of cells through 
relevant transporters.  
1.4.2 15-PGDH substrates 
Although 15-PGDH was first identified as an enzyme which degraded PGs, 
subsequent studies revealed that LOX-type products, such as 15(S)-HETE, 
12-HHT, and 12-HETE were also the substrates of 15-PGDH isolated from 
human IL-60 leukemia cells (28). However, based on the data obtained 
(Table 1.1), it was concluded that substrates containing -6 hydroxyl group 
were more readily degraded by 15-PGDH. This suggests that 15-PGDH could 
play an important role in the metabolism of many different eicosanoids. 
1.4.3 15-PGDH and diseases 
It has been reported that in many tumors and cancer cell lines, 15-PGDH is 
down-regulated so that pro-proliferative PGs can accumulate (29). Eruslanov 
et al. showed that delivery of 15-PGDH genes to mouse tumors greatly 
reduces tumor development through increasing 15-PGDH expression and 
removing accumulated PGE2 (30). Moreover, decreased PGE2 levels not only 
decreased tumor growth rate, but also inhibited the release of 
immunosuppressive cytokines from CD11b cells associated with tumor cells. 
Thus, besides COX-2, 15-PGDH is also a chemotherapy target. Another group 
showed that COX-2 inhibitor therapy fails in some patients who are 15-PGDH 
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deficient, suggesting that a combination of COX-2 inhibitors and 15-PGDH 
stimulators provide a better chemoprevention approach (31).  
 
Table 1.1. Substrate specificity of 15-prostaglandin dehydrogenase 
obtained from HL-60 cells. hydroxyl-heptadecatrienoic acid (HHT); 
hydroxyl-octadecadienoic acid (HODD); hydroxyl-eicosatetraenoic acid 
(HETE).  Activity with PGE2 was 5.4 nmol/min/mg protein. (Modified from 
Table 1.1 in Metabolism of cyclooxygenase and LOX products by 15-PGDH 
from human HL-60 leukemia cells (28) 
 
1.5 Lipid hydroperoxide Non-enzymatic decomposition 
pathway 
1.5.1 Hock rearrangement 
For many years, it has been known that unsaturated lipids can generate 
aldehydes, and compared to the lipid precursor, these aldehydes are much 
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more reactive to cellular macromolecules and thiols. It was reported that 
these aldehydes can modify proteins, DNA, and induce oxidative stress by 
conjugating to GSH. Among these aldehydes, the formation of 
malondialdehyde (MDA), 4-hydroxy-2(E)-nonenal (HNE), and 4-oxo-2(E)-
nonenal (ONE) are the most widely studied (32). However, the mechanism 
by which the aldehydes are formed is still controversial. The Figures 1.6 
to1.10 show some of the mechanisms proposed by different research groups. 
 
 
Figure 1.6: Hock rearrangement, modified from the book 
Comprehensive Organic Name Reactions and Reagents, by Zerong 
Wang, (34) 
 
The Hock rearrangement (or Hock cleavage) was first studied by Hock and 
Schrader in 1936 (33). This reaction is initiated by protic or Lewis acid, which 
promotes the rearrangement of hydroperoxides which have unsaturated 
group (aryl or vinyl) attached to the carbon bearing the hydroperoxide group, 
followed by the formation a oxycarbonium ion, which is further attacked by 
water, initiating another rearrangement. This whole process can convert long 
chain unsaturated fatty acid into shorter chain carbonyl compounds. This 
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mechanism is still often used to explain the conversion of lipid 
hydroperoxides to reactive aldehydes. 
1.5.2 Beta scission 
 
 
 
Figure 1.7. Decomposition mechanism via formation of allylic radicals 
 
This mechanism was originally proposed by the Marnett group (35). The 
hydroperoxide group is reduced by iron, forming alkoxyl radical, which either 
attacks the neighboring unsaturated carbon to form epoxide containing an 
allylic radical (epoxyallylic radical), or undergo β-scission to break a carbon 
bond and form an aldehyde together with an allylic radical, although the 
former pathway is favored. The beta-scission products account for less than 
 
 
18 
5% of the products. Another observation from the same group is that very 
little alcohol is formed, which means most of the alkoxyl radicals don’t stay 
long enough to abstract hydrogen from other molecules, instead, they tend 
to form epoxyallylic radicals, which are much more stable than the alkoxyl 
radicals.  
1.5.3 Dihydroperoxide formation 
 
 
 
Figure 1.8. Hock rearrangement via dihydroperoxide formation from 
5(S)-HPETE 
 
The scheme shown in Figure 1.8 was originally proposed by the Blair group 
(36). There is no direct evidence for the formation of the dihydroperoxide, 
but there was one indirect piece of evidence to support this mechanism. 
Three products, 4-hydroperoxy-2-nonenal (HPNE), ONE and 5,8-dioxo-6(E)-
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octenoic acid were detected as their corresponding 2’-deoxyguanosine 
adducts.  
 
Figure 1.9: Direct hock-cleavage from 9(S)-HPODE and 2-step 
dihydroperoxide formations from 13(S)-HPODE. This figure is modified 
from (37) 
 
The mechanism shown in Figure 9 was originally proposed by the Brash 
group to explain why 9(S)-hydroperoxyoctadecadienoic acid (HPODE) 
generated racemic 4-HPNE, whereas 13(S)-HPODE generated 
enantiomerically pure 4(S)-HPNE (37).  The 9(S)-HPODE has a 
hydroperoxide attached to C9 and also a conjugate double bond next to this 
C9 carbon, which facilitates the vinyl migration during the Hock-
rearrangement. In the case of 13(S)-HPODE, the direct Hock-rearrangement 
product was also observed, but to generate HPNE, another hydroperoxide 
group must be first formed at C10. However, the Brash group subsequently 
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synthesized the dihydroperoxide intermediate, 10,13-dihydroperoxy-HPODE, 
and showed that no HPNE could be detected from this intermediate under 
autoxidation condition.  In contrast, under acidic conditions, HPNE formation 
could be observed. This indicated that conjugated diene group was a better 
migratory group compared to vinyl group during the Hock-rearrangement. In 
order to explain these finding, the Brash group proposed an alternative 
mechanism (37,38). This involved the formation of trimers or oligomers 
derived from 15(S)-HPETE (Figure 1.10).    
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Figure 1.10: Proposed trimer and oligomer formation during 15(S)-
HPETE decomposition (38). 
1.6 Effects of AA-derived electrophiles on proteins and DNA 
1.6.1 Carboxylic acid containing-electrophiles. 
As discussed previously, carboxylic acid containing-electrophiles such as 15d-
PGJ2 (downstream metabolite of PGD2) can be formed from enzymatic 
pathways. All of these electrophiles contain an α-β unsaturated ketone and 
so can potentially react with proteins, GSH or DNA. The possible 
detoxification pathways are to reduce the conjugated ketone or the double 
bond to undergo GST-mediated conjugation with GSH. The metabolites are 
then secreted from the cells. These carboxylate-containing α,β-unsaturated 
ketone metabolites can have significant biological effects before they degrade. 
For example, 15d-PGJ2 is a ligand for the peroxisome proliferator-activated 
receptor gamma (PPAR) receptor and once 15d-PGJ2 binds to PPAR it 
translocates from the cytosol into the nucleus. The PPARγ then binds to DNA 
and regulates the transcription of target genes. The up- or down-regulation 
of these genes can activate adipocyte differentiation, reduce inflammation 
and also have anti-proliferation effects. (4) 
1.6.2 Non-carboxylic acid containing-electrophiles.  
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As discussed previously, aldehydes that are generated by lipid oxidation such 
as MDA, HNE and ONE are bifunctional electrophiles that can react with 
numerous cellular targets. The effects of these aldehydes on modifying 
proteins, DNA and GSH have been intensively studied as described below. 
1.6.2.1 Modification of proteins: 
Lipid peroxidation generated electrophiles tend to modify proteins through 
covalent conjugation with cysteine, histidine, and lysine residues. 
Immunostaining measured protein adducts from glycoxidation, lipid oxidation, 
and acrolein has been analyzed in healthy subjects or patients with diabetic 
nephropathy (DN) or with IgA nephropathy (IgA-N) (Table 1.2) (39). This 
study clearly showed that the lipid oxidation products, MDA and HNE form 
proteins adducts in DN or IgA subjects, while there are only trace adducts in 
healthy subjects, which highlights the relationship between lipid oxidation 
and DN or IgA nephropathy development. 
 
Table 1.2 Results of immunostaining for glycoxidation products, lipid 
oxidation products, and acrolein-protein adduct in healthy subjects 
and patients with diabetic nephropathy (DN) or IgA nephropathy 
(IgA-N). CML, carboxymethyllysine; MDA-lysine, malondialdehyde-lysine; 
HNE-Protein, 4-hydroxy-nonenal-lysine. 
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HNE generated from COX-mediated AA oxidation can even up-regulate the 
expression of COX-2, and function as a positive feedback loop, which further 
increases COX-2 products, resulting in “carbonyl stress” and oxidative stress. 
(40) 
1.6.2.2 Modifications of DNA: 
2’-Deoxynucleosides (except thymidine) have primary amine groups, which 
are good nucleophiles and could be the targets of electrophiles. The reactions 
of different lipid oxidation-derived electrophiles with 2’-deoxyguanosine 
(dGuo) and 2'-deoxyadenine (dAdo) are shown in Figure 1.11 (41). It has 
been reported that dGuo adducts are detected in vivo at higher levels than 
dAdo and 2’-deoxycytidine (dCyd) adducts. ONE and HNE DNA adducts can 
only come from lipid oxidation, while MDA can arise from other sources such 
as during thromboxane A2 biosynthesis. Therefore, ONE- and HNE-derived 
DNA-adducts are good biomarkers for lipid oxidation. Normally, cells have an 
efficient DNA repair system, and once damaged DNA is recognized, they 
either remove the damaged oligonucleotides (nucleotide excision repair, NER) 
or only the damaged bases (base excision repair, BER). The excised 
damaged oligonucleotides or bases would be excreted, and it might be 
possible to detect them in urine. Thus, the HNE and ONE modified 
oligonucleotides or bases could potentially be lipid oxidation and DNA 
damage biomarkers. These DNA adducts are mutagenic if not repaired, they 
would accumulate and could be ultimately responsible for tumorigenesis.  
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Figure 1.11, Scheme of dGuo or dAdo adducts from ONE, HNE, MDA 
and trans-4,5-epoxy-2(E)-decenal (EDE) (41). 
 
1.6.2.3 Inactivation of HNE 
Similar to the inactivation of carboxylate-containing electrophiles, the 
aldehyde moiety of HNE is also subject to reduction to an alcohol by aldo-
keto reductases (AKRs), particularly the AKR1B subfamily isoenzyme: 
AKR1B1. Moreover, HNE is also the substrate of GSTs (42), which catalyze 
the addition of GSH (Figure 1.12). Conjugation can also occur directly 
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through a chemical reaction in the absence of GSTs. Thus, measurement of 
HNE-GSH adduct could be strategy to monitor the lipid peroxidation level.  
 
 
Figure 1.12 The detoxification of HNE by GST and AKR. Modified from 
(42) 
1.7   Brief description of mass spectrometry (MS) methods 
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1.7.1 Three components: 
All mass spectrometers have three components, an ion source, an analyzer 
and a detector.  
The most widely used ion source uses atmospheric pressure ionization (API), 
which is usually coupled with liquid chromatography (LC). Analytes are 
charged in solution by adjusting the pH of the mobile phase.  They are 
allowed to evaporate from the liquid mobile phase into the gas phase 
(electrospray ionization, ESI) or by applying a charged needle under 
atmospheric pressure (atmospheric pressure chemical ionization, APCI). High 
temperature (200 to 400 °C) and nitrogen gas help the desolvation process.  
The mass analyzer is used to distinguish ions with different mass to charge 
ratios (m/z). The ability of the mass spectrometer to distinguish ions of 
different m/z depends upon the resolving power of the mass spectrometer 
that is used.  The definition of resolution is the minimum m/z peak 
separation divided by m/z. For high resolution, such as the LTQ-Orbitrap 
(Thermo Electron, San Jose, CA), it could be up to 150,000, which means 
that it would be possible to distinguish two ions that differ in mass by only 
0.001 Da.  In contrast, low resolution instruments, which typically operate at 
unit mass resolution, can only distinguish two ions that differ in mass by 0.1 
Da. Low resolution mass spectrometers include triple stage quadrupole (TSQ) 
and linear ion trap (LTQ) instruments. TSQs are normally used for 
quantitative studies, while ion traps are more widely used for structure 
elucidation due to its multiple fragmentation function. 
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1.7.2 TSQ quantitation: 
 
Figure 1.13 A simplified example of how the TSQ separates peptide 
ions with different m/z values. 
The TSQ instrument has three quadrupoles (Q) in serial. Q1 and Q3 can work 
in scanning mode, where all of the ions are allowed to pass through and 
recorded by detector, while Q2 is designed to function as a collision cell, 
which means the voltage and collision gas will apply to this cell and fragment 
the ions coming from Q1. The most frequently applied mode with the TSQ is 
selected reaction monitoring (SRM). Under this mode, Q1 is responsible for 
allowing only a selected parent ion to pass through, while in Q2, this ion is 
fragmented and only selected product ion is allowed to fly to Q3 and 
recorded. (MRM usually refers to multiple product ions from a single parent 
ion). LC-SRM/MS is highly selective even with only unit resolution because 
specificity is conferred by the fragmentations process.  The method is also 
highly sensitive and reproducible. Thus, this LC-SRM/MS is widely used in 
lipid metabolite and quantification. 
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Chapter 2  11-Oxo-Eicosatetraenoic Acid is a 
Cyclooxygenase-2/15-Hydroxyprostaglandin 
Dehydrogenase-Derived Anti-Proliferative Eicosanoid 
 
2.1 ABSTRACT 
Previously, the Blair laboratory established that 11(R)-HETE was a significant 
COX-2-derived AA metabolite in epithelial cells.  Stable isotope dilution chiral 
LC-electron capture atmospheric pressure chemical ionization (ECAPCI)/MS 
was used to quantify COX-2-derived eicosanoids in the human colorectal 
adenocarcinoma (LoVo) epithelial cell line, which expresses both COX-2 and 
15-PGDH. 11(R)-HETE secretion reached peak concentrations within minutes 
after AA addition before rapidly diminishing, suggesting further metabolism 
had occurred.  Surprisingly, 15-PGDH, which is normally specific for oxidation 
of eicosanoid 15(S)-hydroxyl groups, was found to convert 11(R)-HETE to 
11-oxo-ETE.  Furthermore, LoVo cell lysates converted 11(R)-HETE to 11-
oxo-ETE and inhibition of 15-PGDH with 5-[[4-ethoxycarbonyl) phenyl]azo]-
2-hydroxy-benzeneacetic acid (CAY 10397) (50 µM) significantly suppressed 
endogenous 11-oxo-ETE production with a corresponding increase in 11(R)-
HETE.  These data confirmed COX-2 and 15-PGDH as enzymes responsible 
for 11-oxo-ETE biosynthesis. Finally, addition of AA to the LoVo cells resulted 
in rapid secretion of 11-oxo-ETE into the media, reaching peak levels within 
20 min of starting the incubation. This was followed by a sharp decrease in 
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11-oxo-ETE levels. GST was found to metabolize 11-oxo-ETE to the 11-oxo-
ETE-GSH (OEG)-adduct in LoVo cells, as confirmed by LC-MS/MS analysis.  
Bromodeoxyuridine (BrdU)-based cell proliferation assays in human umbilical 
vein endothelial cells (HUVECs) revealed that the half-maximal inhibitory 
concentration (IC50) of 11-oxo-ETE for inhibition of HUVEC proliferation was 
2.1 µM.  These results show that 11-oxo-ETE is a novel COX-2/15-PGDH-
derived eicosanoid, which inhibits endothelial cell proliferation with a potency 
that is similar to that observed for 15d-PGJ2. 
2.2 INTRODUCTION 
In an earlier study, the Blair laboratory established that 11(R)-HETE was a 
significant COX-2-derived AA metabolite in epithelial cells (43). However, the 
consequences of this finding were not clear at that time. A number of toxic 
substances including arsenite (44), dioxin (45) benzo[a]pyrene-diol-epoxide 
(46), and cigarette smoke (47) up-regulate COX-2 expression, which in turn 
regulates numerous intracellular biochemical pathways. This occurs primarily 
through the biosynthesis of COX-2-derived AA metabolites, which can exert 
cell-specific effects on inflammation, cell growth, and proliferation. For 
example, COX-2-derived prostaglandin (PG) E2 increases tumor proliferation 
through multiple mechanisms including activation of plasma membrane G-
protein-coupled receptors and the nuclear peroxisome proliferator-activated 
receptor (PPAR).(48) 
Steady-state levels of PGE2 are maintained by PGE-synthase-mediated 
biosynthesis from COX-2-derived PGH2 and catabolism by 15-PGDH-mediated 
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inactivation to 15-oxo-PGE2 (Figure 2.1).(49,50) The 15-oxo-PGE2 is then 
converted to 13,14-dihydro-15-oxo-PGE2 by 15-oxo-prostaglandin-
13 
reductase.(51)  Loss of 15-PGDH expression is associated with tumor 
formation in bladder, breast, colon, intestine, kidney, lung, pancreas, 
stomach, and skin cancer.(49,50,52-54)  Thus, up-regulation of COX-2 (48) 
and down-regulation of 15-PGDH (52) provides a switch towards endogenous 
mediators that are significant contributors to cancer progression.(57) 
PGD2, another COX-2-derived metabolite, is also metabolized by 15-PGDH to 
form 15-oxo-PGD2, which is then converted to the corresponding inactive 
13,14-dihydro-derivative (Figure 2.1).(58) Alternatively, PGD2 undergoes 
albumin-mediated dehydration to give PGJ2, followed by a further 
dehydration to give 15-deoxy-12,14-prostaglandin J2; (15d-PGJ2) (Figure 
2.2).(59) Previous studies have shown that 15d-PGJ2 is a PPAR agonist,(60) 
which inhibits HUVEC proliferation in culture.(61) In addition, 15d-PGJ2 can 
induce caspase-mediated endothelial cell apoptosis(62) and inhibit the 
nuclear factor κB (NFB) pathway.(63-64)  It can also increase levels of p53 
in HUVECs, activate p53 phosphorylation, and induce p21.(65)  
Studies of purified COX enzymes have shown that 11(R)-HETE, 15(S)-HETE, 
and 15(R)-HETE are the major HETEs that are formed.(66) The HETEs arise 
from reduction of the corresponding HPETEs primarily through the peroxidase 
(POX) activity of COXs (Figure 2.1).(67) 11(R)-HETE was a significant 
eicosanoid secreted by AA-treated rat intestinal epithelial cells that stably 
express COX-2 (RIES cells) but it was rapidly metabolized.(43) 15(S)-HETE 
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was formed in lower abundance and metabolized to 15-oxo-ETE (66,68) as 
expected from its 15(S)-configuration and the substrate specificity of 15-
PGDH. 15-Oxo-ETE was also found to inhibit endothelial cell proliferation, 
although at concentrations higher than 15d-PGJ2.(68)  However, there is little 
evidence that 15d-PGJ2 can be formed in vivo at concentrations 
commensurate with an endogenous anti-proliferative role.(69)  In our earlier 
study, (43) the metabolic fate of 11(R)-HETE secreted by the RIES cells was 
not established. 11-Oxo-ETE has now been synthesized and a LC-selected 
reaction monitoring (SRM)/MS method for its analysis has been developed. 
This has made it possible to determine whether 11-oxo-ETE is secreted by 
human epithelial cell lines with up-regulated COX-2 expression and to 
identify the dehydrogenase responsible. The ability of 11-oxo-ETE to 
modulate HUVEC proliferation has also been examined. 
 
 
 
 
 
32 
 
Figure 2.1. Formation and action of COX-2-derived eicosanoids in 
epithelial cell models.  AA is released from membrane phospholipids by 
calcium-dependent cytosolic phospholipase A2 (cPLA2).  The released AA 
undergoes COX-2-medaited metabolism to PGs or forms the lipid 
hydroperoxides, 15(S)-hydroperoxyeicosatetraenoic acid; (HPETE), 15(R)-
HPETE and 11(R)-HPETE, which are reduced to the corresponding HETEs. 
PGD2 and PGE2 are inactivated by 15-PGDH-mediated conversion to their 15-
oxo-metabolites.  Both 15-oxo-PGD2 and 15-oxo-PGE2 are converted to 
13,14-dihydro-5-oxo-PG metabolites.  Intact PGD2 secreted by the epithelial 
cells can undergo albumin-mediated dehydration to 15d-PGJ2. PGE2 secreted 
from the epithelial cells by the ABCC4 transporter is pro-proliferative for 
tumor cells.  Re-uptake of PGE2 by OATP2A1 into the epithelial cells leads to 
further 15-PGDH-mediated inactivation.  In contrast to PGE2 and PGD2, 
15(S)-HETE and 11(R)-HETE are activated by 15-PGDH-mediated oxidation 
to 15-oxo-ETE and 11-oxo-ETE, respectively. The oxo-ETEs are further 
conjugated to form OEGs.  Secreted 15- and 11-oxo-ETE that escape further 
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metabolism can then inhibit endothelial cell proliferation. Therefore, down-
regulation of 15-PGDH and OATP2A1 would result in increased PGE2-
mediated tumor and endothelial cell proliferation. 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. Chemical structures of COX-2 derived eicosanoids. 
 
2.3 EXPERIMENTAL PROCEDURES 
2.3.1 Chemicals and Reagents.  
AA (peroxide-free), 11(R,S)-HETE, 15(R,S)-HETE, [2H8]-15(S)-HETE, [
13C20]-
15-oxo-ETE, 15-oxo-ETE, PGE2, [
2H4]-PGE2, 13,14-dihydro-15-keto-PGE2, 
[2H4]-13,14-dihydro-15-keto-PGE2, 15d-PGJ2, CAY10397, protease inhibitor 
cocktail and recombinant human 15-PGDH were purchased from Cayman 
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(Ann Harbor, MI).  The Dess-Martin reagent [1,1,1-Tris(acetyloxy)-1,1-
dihydro-1,2-benziodoxol-3-(1H)-one], 2,3,4,5,6-pentafluorobenzyl (PFB) 
bromide, Trizma-HCl, lipoxidase from Glycine max (soybean), sodium 
borohydride, and NAD+ were purchased from Sigma-Aldrich (St. Louis, MO). 
Fetal bovine serum (FBS) was from Gemini Bioproducts (West Sacramento, 
CA). F12K medium, DMEM medium, Medium 200 (M200), Minimum Essential 
Medium (MEM), D-glucose, L-glutamine, low-serum growth supplement 
(LSGS) kit, penicillin, and streptomycin were supplied by Invitrogen 
(Carlsbad, CA). LC-MS grade water, hexane, methanol, isopropanol, 
acetonitrile and dichloromethane were obtained from Fisher Scientific 
(Pittsburgh, PA).  Gases were supplied by The Linde Group (Munich, 
Germany).  [13C20]-AA was obtained from Spectra Stable Isotopes (Columbia, 
MD). 
2.3.2 Cell Culture.  
Human colorectal adenocarcinoma LoVo cells (ATCC, Manassas, VA) were 
cultured in F12K medium supplemented with 10% FBS, 2 mM/L glutamine, 
100,000 units/l penicillin and 100 mg/l streptomycin. Human colonic 
adenocarcinoma HCA-7 Colony 29 cells (Sigma-Aldrich, St. Louis, MO) were 
grown in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 110 mg/L 
sodium pyruvate, 100,000 units/l penicillin and 100 mg/l streptomycin. For 
lipidomics analysis, the culture media was replaced with serum-free F12K or 
DMEM media before the treatment.  HUVECs were obtained from Invitrogen 
(Carlsbad, CA), and cultured on collagen I-coated tissue culture dishes in 
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Medium 200 supplemented with LSGS kit. Caco-2 cells were grown in MEM 
containing 20% FBS 2 mM/L glutamine, 100,000 units/l penicillin and 100 
mg/l streptomycin. Cell proliferation assays were performed using HUVECs 
from passage 4. 
2.3.3 Mass Spectrometry.  
A triple stage quadrupole (TSQ Quantum) mass spectrometer (Thermo 
Electron, San Jose, CA) equipped with an APCI source was used for the 
quantitative lipidomics analyses. Targeted chiral LC-ECAPCI/SRM/MS analysis 
was conducted using PFB derivatives of 7 lipids and 4 heavy isotope analog 
internal standards.  For the lipidomics profile, the instrument was operated in 
the negative ion mode, and unit resolution was maintained for both precursor 
and fragment ions.  Operating conditions for the TSQ Quantum were: 
vaporizer temperature at 450°C; heated capillary temperature at 250 °C with 
the corona discharge needle set at 30 µA; nitrogen as sheath (25 psi) and 
auxiliary (5 arbitrary units) gas. Collision-induced dissociation (CID) was 
performed using argon as the collision gas at 2.7 mtorr in the RF-only 
quadrupole. The following SRM transitions were used: 11-oxo-ETE-PFB, m/z 
317 → 165 (collision energy (CE), 25 eV), 15-oxo-ETE-PFB, m/z 317 → 113 
(CE, 18 eV), [13C20]-15-oxo-ETE-PFB, m/z 337 → 120 (CE, 18 eV), 11(R)-
HETE-PFB, m/z 319 → 167 (CE, 16 eV), [2H8]-15(S)-HETE-PFB, m/z 327 → 
226 (CE, 13 eV), PGE2-PFB, m/z 351 → 271 (CE, 18 eV), [
2H4]-PGE2-PFB, 
m/z 355 → 275 (CE, 18 eV). 13,14-dihydro-15-keto-PGE2-PFB, m/z 351 → 
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235 (CE, 22 eV), [2H4]-13,14-dihydro-15-keto-PGE2-PFB, m/z 355 → 239 (CE, 
22 eV). 
For GSH adduct analysis, the mass spectrometer was operated in the positive 
ion mode with an electrospray ionization (ESI) source.  The operating 
conditions were: spray voltage at 4 kV; capillary temperature at 350°C; 
nitrogen as sheath (35 psi) and auxiliary (13 arbitrary units) gas. CID was 
performed using argon as the collision gas at 2.7 mtorr in the Rf-only 
quadrupole.  The following SRM transition (m/z 626 → 497) was monitored 
for 11-oxo-ETE-GSH (CE, 18 eV).   
2.3.4 Liquid Chromatography.  
LC separations were conducted using a Waters® Alliance 2690 HPLC system.  
A Chiralpak AD-H column (250 × 4.6 mm inner diameter, 5 µm; Daicel) was 
employed for normal phase separation (flow-rate 1 ml/min) of PFB-
derivatives of eicosanoids.  Gradient 1 was used for separating PFB-
derivatives of HETEs and PGE2, whereas gradient 2 was used for PFB 
derivatives of oxo-ETEs. For gradient 1, solvent A was hexane, and solvent B 
was methanol/isopropanol (1:1; v/v).  Gradient 1 was as follows: 2% B at 0 
min, 2% B at 3 min, 3.6% B at 11 min, 8% B at 15 min, 8% B at 27 min, 50% 
B at 30 min, 50% at 35 min, and 2% B at 37 min.  Separations were 
performed at 30°C using a linear gradient. For gradient 2, solvent A was 
hexane, and solvent B was isopropanol/hexane (6:4; v/v). Gradient 2 was as 
follows: 2% B at 0 min, 2% B at 14.5 min, 12% B at 15 min, 23% B at 19 
min, 90% B at 19.5 min, 90% B at 23.5 min, and 2% B at 24 min. 
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A Chiralpak AD-RH column (150 × 4.6 mm inner diameter, 5 µm; Daicel) 
was used for reverse phase (isocratic method 1, flow-rate 0.5 ml/min) 
separation of the un-derivatized 11-oxo-ETE. The mobile phase for isocratic 
separations was methanol/water/formic acid (95:5:0.1; v/v). 
Chemically synthesized 11-oxo-ETE was purified by normal-phase (isocratic 
method 2) preparative LC (Ultrasphere™ 250 × 10 mm, inner diameter, 5 
µm; Beckman) using Hitachi LC system by monitoring the UV absorbance at 
236 nm.  The mobile phase for isocratic method 2 (flow-rate 2.5 ml/min) was 
hexane/isopropanol/acetic acid (98.5:1.5:0.1; v/v). 
GSH adducts were separated by reverse phase using gradient 3 on Waters® 
Alliance 2690 HPLC system. The separation employed a Phenomenex Synergi 
Hydro-RP column (150 × 4.6 mm inner diameters, 5 µm). Solvent A was 0.1% 
aqueous formic acid, and solvent B was methanol/acetonitrile (50:50; v/v).  
Gradient 3 was as follows: 2% B at 0 min, 2% B at 14 min, 30% B at 20 min, 
42% B at 21 min, 65% B at 27 min, 80% B at 29 min, 90% B at 33 min, 90% 
B at 34 min, 2% B at 35 min. The flow rate was 0.4 ml/min.  The separation 
was performed at ambient temperature using a linear gradient. 
2.3.5 PFB Derivatization.  
Eicosanoids were dissolved in 100 µl of acetonitrile, and then reacted with 
100 µl of PFB bromide in acetonitrile (1:19; v/v) and 100 µl of 
diisopropylethylamine in acetonitrile (1:9; v/v) at room temperature for 30 
min. The derivatives were evaporated to dryness, dissolved in 100 µl of 
hexane/ethanol (95:5; v/v) and analyzed by chiral LC-ECAPCI/SRM/MS. 
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2.3.6 Enzymatic Conversion of 11(R)-HETE by 15-PGDH. 
 Various concentrations of 11(R)-HETE (0, 2.3 M, 4.6 M, 6.9 M, 9.2 M 
and 23 M) were incubated with 4 nM of recombinant human 15-PGDH (50 
ng, 1.8 pmol) and cofactor NAD+ (400 M) in 50 mM Tris-Cl (pH 7.9) for 3.5 
min at 37 oC.  Each total reaction volume was 200 l. After a 3.5 min 
incubation, the enzymatic reaction was quenched with 400 l of ice cold 
methanol and [13C20]-15-oxo-ETE (8 ng) added as the internal standard. 
Eicosanoids were extracted with 1.2 ml of dichloromethane/methanol (8:1; 
v/v). The lower organic layer was then evaporated to dryness under nitrogen 
and reconstituted in methanol (100 l). An aliquot (25 µl) was separated 
using isocratic method 1 and analyzed by LC-ESI/MS as described above. The 
retention time for 11-oxo-ETE was 8.7 min. In separate experiments, the 
formation of 11-oxo-ETE was found to be linear for the first 5 min. 
Eicosanoids were quantified by interpolation from a standard curve prepared 
with 11-oxo-ETE using [13C20]-15-oxo-ETE as the internal standard. 
2.3.7 Chemical Synthesis and Purification of 11-Oxo-ETE.  
The Dess-Martin reagent (5 mg, 12.0 mol) was added to a solution of 
11(R,S)-HETE (10 mg, 31.0 µmol) in dichloromethane (0.5 ml) and stirred 
for 2 h at room temperature.  The reaction was monitored by LC-MS using 
gradient 1 as described above, after PFB derivatization until there was no 
starting material left.  There was only one major product, which 
corresponded to 11-oxo-ETE. The reaction mixture was centrifuged twice at 
3,400 rpm (10 min) and the supernatant was evaporated.  The residue was 
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dissolved in the mobile phase (800 l) and purified by isocratic method 2 as 
described above. The retention time for 11-oxo-ETE was 13.1 min.  High 
resolution accurate mass measurements were obtained using electrospray 
ionization on a Thermo LTQ-FT mass spectrometer at a resolution of 100,000 
(data not shown). NMR spectra were obtained on a Bruker 500 MHz NMR 
instrument. 
2.3.8 15-PGDH inhibition in LoVo or HCA-7 Cell Lysates by CAY10397. 
LoVo or HCA-7 cells were grown to 90% confluence, washed with 10 ml of 
phosphate-buffered saline (PBS) buffer (2 times), and then gently scraped in 
600 µl of lysis buffer containing 0.1 M Tris-HCl (pH 7.9) and the protease 
inhibitor.  Cell suspension was transferred to 2 ml Eppendorf tubes, and 
sonicated for 60 seconds on ice (power 5).  Cell lysate was then incubated 
with or without the selective 15-PGDH inhibitor (CAY10397, 50 M) and its 
co-factor (NAD+, 500 µM) for 10 min at 37°C.  The pH was then adjusted to 
4 with 10% aqueous acetic acid (10 µl) followed by addition of the internal 
standard mix, [13C20]-15-oxo-ETE, [
2H8]-15(S)-HETE and [
2H4]-PGE2 (50 
pg/µl, 20 µl). Diethyl ether (600 µl) was added, and samples were vortex-
mixed and centrifuged (15000 rpm×2 min). The organic layer was 
evaporated under nitrogen, and then the eicosanoids were derivatized with 
PFB bromide as mentioned above. Finally, samples were re-dissolved in 
hexane/ethanol (95:5; v/v, 100 µl), and analyzed (20 µl) by normal phase 
LC-ECAPCI/MS.  The amounts of eicosanoids were normalized by protein 
concentrations of each lysate, which were determined by BCA assay. 
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2.3.9 Metabolism of AA by LoVo or HCA-7 Cells.  
LoVo or HCA-7 cells were grown to 90% confluence in 6-well plates as 
described above, and then fed fresh serum-free F-12K or DMEM medium. 
Cells were then incubated with AA (10 µM) for 0, 5, 10 and 30 min, 1 and 2.5 
h at 37°C.  At each time point, 0.6 ml medium was taken out, 20 µl 10% 
aqueous acetic acid was added to adjust pH to 3-4, together with 20 µl 
internal standards mixture (50 pg/ µl [12C20]-15-oxo-ETE, [
2H8]-15(S)-HETE, 
[2H4]-PGE2 and [
2H4]-13,14-dihydro-15-keto-PGE2-PFB).  Then diethyl ether 
(1 ml) was added, and the mixture was vortex-mixed and centrifuged (15000 
rpm × 2 min). The upper ether layer was evaporated under nitrogen, and 
PFB derivatives were synthesized as described above and analyzed by normal 
phase LC-ECAPCI/MS. 
2.3.10 Standard curves for Eicosanoid Quantification.  
To quantify eicosanoids excreted in the medium, Eppendorf tubes containing 
0.6 ml F12K medium were spiked with lipid standards, together with internal 
standards for ([12C20]-15-oxo-ETE, [
2H8]-15(S)-HETE ,[
2H4]-PGE2 and [
2H4]-
13,14-dihydro-15-keto- PGE2-PFB 1 ng each). To quantify eicosanoids in the 
cell lysate, lipids standards and internal standards mixture were spiked into 
0.2 ml Tris-HCl buffer. The extraction and PFB derivatization methods are the 
same as mentioned above. 
2.3.11 Analysis of 11-OEG adducts in LoVo cell lysate.  
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LoVo cells were grown to 90% confluence and then washed with PBS (10 ml). 
Cells were gently scraped in 600 µl Tris-HCl buffer (0.1 M, pH=7.9), 
containing protease inhibitor. Cell lysates were transferred to 2 ml Eppendorf 
tubes, and sonicated for 60 seconds on ice (power 5). 11-oxo-ETE (20 ng in 
ethanol) was added to the lysate together with 1 mM GSH. After incubation 
for 25 min at 37°C, 10 µl of 10% acetic acid was added, and the sample was 
loaded onto SPE column (oasis HLB, 30 mg) pre-conditioned with methanol 
and then 0.1% formic acid. The column was washed with 1 ml water and 
eluted with 250 µl methanol, and then 20 µl was analyzed by reverse phase 
LC-ESI/MS using gradient 3, as described above. 
2.3.12 Conversion of 11-oxo-ETE and 15-oxo-ETE to 11(S)-HETE and 
15(S)-HETE in Caco-2 cell lysate.  
Caco-2 cell lysate was prepared in the same way as LoVo cell lysate, and 
then NADH (100 M), NADPH (100 M), 11-oxo-ETE (100 nM) and [13C20]-15-
oxo-ETE (100 nM) were added. For the control sample, no oxo-ETEs were 
added. The mixtures were kept at 37 °C for 10 min before lipid extraction. 
The extraction and PFB derivatization procedures were the same as described 
above. 
2.3.13 Cell proliferation assay.  
BrdU incorporation in HUVECs was used to assess the effects of 11-oxo-ETE 
on cell proliferation. The BrdU assay was performed in a 96-well format using 
a commercially available colorimetric enzyme-linked immunosorbent assay 
(ELISA) kit (Roche), and also by immunofluorescence microscopy. Equal 
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numbers of HUVECs in passage 4 were plated in either, collagen-I coated 96-
well plates (2000 cells/well), or collagen-I coated 8-chamber tissue culture 
glass slides (10000 cells/chamber). Cells were allowed to attach overnight in 
0.25% DMSO containing media. Eicosanoids were dissolved in DMSO, such 
that the final concentration of DMSO in cell media was always 0.25% or 
lower. Cells were then treated for 24 h with either vehicle (0.25% DMSO), 
11-oxo-ETE (1 nM-100 M), or 15d-PGJ2 (1 nM-100 M). After 18 h of 
treatment, BrdU (final concentration, 10 M in 0.25% DMSO) was added to 
each treatment group for an additional 6 h. 
For the colorimetric ELISA, the manufacturer’s protocol was followed to 
perform the assay. The absorbance at λ = 370 nm obtained from the assay 
was transformed to the cell numbers using a standard curve constructed by 
plating known number of HUVECs in triplicate. The IC50 values for eicosanoid 
inhibition of HUVEC proliferation were defined as the half maximal inhibitory 
concentration for endothelial cell proliferation over 24 h when compared with 
vehicle-treated cells. They were determined from the regression lines of the 
log inhibitor vs. response curves using a least squares fit. 
For the immunofluorescence staining, cells were fixed with neutral buffered 
formalin for 10 min, permeabilized with methanol for 20 min, and then DNA 
was denatured by pressure cooking the slides in 10 mM citric acid buffer, pH 
6 for 1 h. Cells were then incubated overnight with rat anti-BrdU antibody 
(1:1000, Accurate Chemical & Scientific Corp.) at 4°C, followed by 30 min 
incubation at 37 °C with Cy3-conjugated donkey anti-rat secondary antibody 
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(1:600, Jackson Immuno Research).  Cells were counterstained with 4',6-
diamidino-2-phenylindole (DAPI, Invitrogen) and visualized using a Nikon 
E600 microscope equipped with differential interference contrast (Nomarski) 
optics and photographed (x200 magnification) with a Fast 1394 QICam 
(QImaging). Positive BrdU staining was quantified by image analysis using 
IVision Analysis Software (Biovision). The percentage of proliferating cells 
was determined by counting the BrdU-positive cells versus the total number 
of cells in randomly selected microscopic fields (10/replicate) for each 
treatment group. 
Statistical Analyses. All experiments were conducted in triplicate, unless 
otherwise indicated. Statistical significance (p value < 0.05) was determined 
using a two-tailed unpaired t-test employing GraphPad® Prism software (v 
5.01). 
 
2.4 RESULTS 
2.4.1 Biosynthesis of 11-oxo-ETE by 15-PGDH.  
Various concentrations of 11(R)-HETE were incubated with recombinant 
human 15-PGDH and NAD+ at 37 °C. A Michaelis-Menten kinetic analysis of 
11-oxo-ETE formation revealed that the Vmax (296 nmol/min/mg), Km (3.42 
M), and kcat (8.6 min
-1) values for oxidation of 11(R)-HETE (Figure 2.3) were 
similar to those for 15(S)-HETE (Km = 1.65 M, kcat =8.6 min
-1;). Therefore, 
the catalytic efficiency (Kcat/Km) for 15-PGDH-mediated oxidation of 11(R)-
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HETE (2513 min-1mM-1, Figure 2.3) was similar to that for 15(S)-HETE (7091 
min-1mM-1;). 
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Figure 2.3. Kinetic plot of the formation of 11-oxo-ETE and 15-oxo-
ETE by 15-PGDH.  Various concentrations of 11(R)-HETE or 15(S)-HETE (0-
23 M) were incubated with 4 nM 15-PGDH and cofactor NAD+.  
Determinations for 11-oxo-ETE were conducted in triplicate (means ± S.E.M.) 
by stable isotope dilution LC-ESI/MS analyses.  
 
2.4.2 Chemical Synthesis of Authentic 11-oxo-ETE.  
11-Oxo-ETE was synthesized chemically by oxidizing racemic 11(R,S)-HETE 
using the Dess-Martin reagent, and then purified using chromatographic 
separation.  A combined total of 10 mg of the racemic 11(R,S)-HETE resulted 
in the isolation of 4.9 mg of pure 11-oxo-ETE (overall yield of 49%). High 
resolution electrospray ionization-MS of 11-oxo-ETE revealed accurate 
masses of m/z 319.2263 and m/z 341.2079 for the protonated and sodiated 
molecules, respectively [calculated accurate mass for protonated (C20H31O3) 
and sodiated (C20H30O3Na) molecules, m/z 319.2273 and m/z 341.2093, 
respectively]. 500 MHz 1H-NMR (H, CDCl3;) 7.55 (dd, J1 = 11.5 Hz, J2 =15.5, 
1H), 6.21(d, J =15.5Hz, 1H), 6.15-6.11 (m, 1H), 5.97-5.92 (m, 1H), 5.60-
5.58 (m, 2H), 5.41-5.38 (m, 2H), 3.35 (d, J =4.5Hz, 2H), 2.83-2.81 (m, 2H), 
2.38-2.31 (m, 4H), 2.17-2.12 (m, 2H), 1.74-1.25 (m, 8H), 0.89 (t, J = 7.0 
Hz, 3H).  Analysis of purified 11-oxo-ETE as its PFB derivative by LC-
ECAPCI/MS (Figure 2.5a) revealed an intense negative ion at m/z 317 
corresponding to [M-PFB]-. CID of [M-PFB]- (m/z 317) and MS/MS analysis 
revealed major product ions at m/z 273, 219, 165, 149, and 123. The UV 
spectrum was consistent with the presence of a conjugated dienone with a 
UV max at 279 nm and molecular extinction coefficient () of 18,985 M
-1cm-1. 
The NMR spectrum data is shown in Figure 2.4. 
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Figure 2.4 500 MHz 1H NMR spectrum of 11-oxo-ETE in CDCl3. 
2.4.3 Confirmation of 11-oxo-ETE Identity by LC-MS and MS/MS 
Analyses.  
The LoVo cell line is known to express both COX-2 and 15-PGDH and only 
trace amounts of COX-1,(52,60) this was confirmed by Western blot analysis 
(data not shown). Cell lysates were incubated with 100 nM 11(R)-HETE in the 
presence of 500 M NAD+ for 10 min. LC-MS analysis of PFB derivatives of 
eicosanoids extracted from the LoVo cell lysate showed that there was a 
single major metabolite, which eluted at 12.8 min (data not shown). The full 
scan mass spectrum of this metabolite had only one major ion at m/z 317 
corresponding to [M-PFB]- (Figure 2.5b).  CID and MS/MS analysis revealed 
the formation of intense product ions at m/z 123, 149, 165, 219, and 273 
(Figure 2.5b).  The product ion spectrum was identical with that obtained 
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from authentic synthetic 11-oxo-ETE-PFB (Figure 2.5a), which confirmed the 
identity of 11-oxo-ETE from LoVo cells. The product ion at m/z 165 in LoVo 
cell-derived and synthetic 11-oxo-ETE-PFB corresponded to cleavage 
between C-9 and C-10 and m/z 123 was formed from cleavage between C-11 
and C-12 (Figure 2.5).   
 
Figure 2.5. Confirmation of 11-oxo-ETE formation by LC-MS/MS 
analysis.  Specific product ions observed by CID and MS/MS analysis of [M-
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PFB]∙ (m/z 317), corresponding to 11-oxo-ETE are shown on the relevant 
chemical structures. (a) Synthetic 11-oxo-ETE-PFB standard; (b) 15-PGDH-
derived 11-oxo-ETE-PFB from LoVo cell lysate to which 100 nM 11(R)-HETE 
had been added. 
 
2.4.4  Separation of Eicosanoids by Chiral LC-ECAPCI/SRM/MS.  
Lysates from LoVo cells were extracted for the eicosanoids, which were then 
analyzed (after PFB derivatization) by LC-ECAPCI/SRM/MS. A representative 
chromatogram (Figure 2.6) reveals the separation of 11-oxo-ETE (retention 
time 12.8 min) and 15-oxo-ETE (retention time 12.0 min) that were formed 
in the LoVo cell lysate.  Additional eicosanoids that were observed (Figure 2.6) 
include, 13,14-dihydro-15-keto-PGE2 (retention time, 33.6 min), 11(R)-HETE 
(retention time, 10.0 min), and PGE2 (retention time, 29.4 min). 
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Figure 2.6. Targeted chiral lipidomics analysis of COX-2 derived 
eicosanoids from LoVo cells.  LoVo cells were lysed; eicosanoids were 
extracted, derivatized with PFB bromide, and analyzed by LC-
ECAPCI/SRM/MS.  LoVo cell lysates were pre-treated with 50 µM CAY10397 
to inhibit 15-PGDH to be able to detect the 11-, 15-HETEs and PGE2.  
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Representative chromatograms are shown for (a) 11(R)-HETE-PFB (m/z319 
→167), (b) [2H8]-15(S)-HETE-PFB internal standard (m/z 327→226), (c) 11-
oxo-ETE-PFB (m/z 317→165), (c) 15-oxo-ETE-PFB (m/z 317→165), (d) 
[13C20]-15-oxo-ETE-PFB internal standard (m/z 337→120), (e) PGE2-PFB (m/z 
351→271), (f) [2H4]-PGE2-PFB (m/z 355→275), (g) 13,14-dihydro-15-oxo-
PGE2-PFB (m/z 351→235), (h) [
2H4]-13,14-dihydro-15-oxo-PGE2-PFB (m/z 
355→239).   
 
2.4.5 Inhibition of 15-PGDH by CAY10397 in LoVo and HCA-7 cell 
lysates.  
In contrast to LoVo cells, the HCA-7 cell line is known to express COX-2 and 
only trace amounts of COX-1 and 15-PGDH (52, 71). This was confirmed by 
Western blot analysis (data not shown). LoVo (Figure 2.7a) or HCA-7 (Figure 
2.7b) cell lysates were incubated with 500 M NAD+, with or without the 15-
PGDH-inhibitor, CAY10397 (50 µM) for 10 min. Inhibition of 15-PGDH 
significantly abolished the formation of endogenous 11-oxo-ETE (Figure 2.7a) 
by 92%, along with the diminished formation of 15-oxo-ETE as well as 
13,14-dihydro-15-oxo-PGE2 (Figure 2.7a) in the LoVo cell lysate. However, 
since the oxo-ETEs and 13,14-dihydro-15-oxo-PGE2 were undetectable in 
HCA-7 cell lysate, their precursors were quantified instead, and CAY10397 
had no effect on their levels (Figure 2.7b). 
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Figure2.7. Inhibition of 15-PGDH in LoVo and HCA-7 cell lysates by 
CAY10397.  (a) LoVo or (b) HCA-7 cell lysate (1x106 cells/treatment group) 
was incubated with or without CAY10397 (50 µM, to inhibit 15-PGDH).  
Eicosanoids were extracted from the lysates and their levels were determined 
by chiral LC-ECAPCI/SRM/MS.  Analyses were performed in triplicates, and 
error bars show S.E.M. 
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2.4.6 Secretion of eicosanoids from LoVo and HCA-7 cells following 
AA addition.  
Time-course analyses for the amount of different eicosanoids secreted by 
LoVo and HCA-7 cells following AA incubation for 0-2.5 h are shown in Figure 
2.8a and Figure 2.8b, respectively. 11-Oxo-ETE was secreted into the cell 
media by LoVo cells along with 15-oxo-ETE and 13,14-dihydro-15-oxo-PGE2 
(Figure 2.8a). Interestingly, both 11-oxo-ETE and 15-oxo-ETE reached 
maximum concentrations 10 min after the addition of AA to the cells. This 
was followed by a decline of both eicosanoids to steady-state levels after 2.5 
h (Figure 2.8a) in LoVo cells. In contrast, 13,14-dihydro-15-oxo-PGE2 levels 
did not peak until 1 h after the addition of AA (Figure 2.8a) and remained 
constant throughout the remainder of the incubation period.  In contrast, 
none of the eicosanoids resulting from 15-PGDH-mediated metabolism were 
detected in the media of HCA-7 cells incubated with AA (Figure 2.8b). 
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Figure 2.8. Time course for eicosanoids secreted from LoVo and HCA-
7 cells following AA incubation. (a) LoVo or (b) HCA-7 cells were 
incubated with 10 M AA for 0-6 h. The different eicosanoids secreted into 
the media at various time-points were extracted and their levels were 
determined by stable isotope dilution LC-ECAPCI/SRM/MS analysis of their 
PFB derivatives. Determinations were conducted in triplicate (means ± 
S.E.M.), and the quantitation was performed using the standard curves 
generated for these eicosanoids. 
 
2.4.7 Formation of 11-OEG in LoVo Cell Lysates.  
Biosynthesis of 11-OEG was monitored in the cell lysate after the addition of 
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was detected and confirmed by LC-MS/MS monitoring of the major 
metabolite formed after a 30 min incubation. OEG (retention time, 32.2 min, 
data not shown) was observed as an intense peak in the LC-ESI/MS 
chromatogram when analyzed by gradient 3 (as described above). CID and 
MS/MS analysis revealed the formation of intense product ions at m/z 497, 
319, 308, and 179 (Figure 2.9). 
 
Figure 2.9. LC-MS/MS analysis of 11-OEG adduct.  11-OEG was 
synthesized by reacting 200 nM 11-oxo-ETE and 1 mM GSH in LoVo cell 
lysate for 25 min at 37°C.  The product was extracted by solid-phase 
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extraction and analyzed by LC-ESI/MS/MS.  Specific product ions observed 
by CID of [MH]+ (m/z 626) are shown with their relevant chemical structures 
in the MS/MS analysis of 11-OEG. 
 
2.4.8 Conversion of 11-oxo-ETE and 15-oxo-ETE to 11(S)-HETE and 
15(S)-HETE in Caco-2 cell lysate.  
Besides detoxification by GST/GSH pathway, oxo-ETEs can also be reduced 
to their alcohol form. This biotransformation was tested in Caco-2 cells by 
adding exogenous 11-oxo-ETE and [13C20]-15-oxo-ETE to the cells lysate, 
together with potential cofactor NADH/NADPH. After analyzing the 
eicosanoids in the lysate, the formation of 11(S)-HETE and [13C20]-15(S)-
HETE was observed. The data are shown in Figure2.10. 
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Figure 2.10 Reduction of 11-oxo-ETE and [13C20]-15-oxo-ETE to 
11(S)-HETE and [13C20]-15(S)-HETE in Caco-2 cell line. Figure2.10(a) 
and 2.10(b) show the basal level of 11-HETE and [13C20]-15(S)-HETE in Caco-
2 cell lysate, while 2.10(c) and 2.10(d) represent the formation of 11(S)-
HETE and [13C20]-15(S)-HETE after treating Caco-2 cell lysate with 100 nM 
11-oxo-ETE and [13C20]-15(S)-HETE for 10 min at 37 °C. 11-HETE was 
monitored as PFB derivative in negative mode by SRM m/z 319→167, while 
[13C20]-15(S)-HETE was monitored by 339→233. The peak in 9(a) and (c) at 
10.1 min is corresponding to 11(R)-HETE, while 11.8 min is 11(S)-HETE. The 
retention time of [13C20]-15(R)-HETE is 11.4 min, while its (S) form is 15.0 
min. 
 
2.4.9 Effects of Eicosanoids on HUVEC Proliferation.  
Proliferation by HUVECs was assessed by quantifying the BrdU incorporation 
into the cells actively synthesizing new DNA. The BrdU assay was performed 
using a quantitative colorimetric 96-well format ELISA as well as by 
immunofluorescence microscopy for observing the morphological effects of 
eicosanoids in HUVECs.  For the BrdU ELISA, HUVECs (2000 cells/well) were 
treated with different doses (0-100 M) of 11-oxo-ETE and 15d-PGJ2 for a 
period of 24h. The cell numbers corresponding to each treatment dose were 
computed and used to calculate cell proliferation (%) as compared to the 
vehicle-treated controls.  11-Oxo-ETE (IC50 = 2.1 M) was equipotent with 
15d-PGJ2 (IC50 = 2.3 M), a known potent inhibitor of endothelial cell 
proliferation (Figure 2.11a). For the immunofluorescence analysis, HUVECs 
(8000 cells/chamber) were treated with 2 M of either 11-oxo-ETE or 15d-
PGJ2 for 24 h.  BrdU incorporation was assessed by counting the BrdU-
positive cells as compared to the total number of cells counted in randomly 
selected microscopic fields (10 fields/treatment).  The photomicrographs 
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clearly show that treatment with 11-oxo-ETE as well as 15d-PGJ2 remarkably 
reduced the total number of BrdU-positive cells (stained red) as compared to 
vehicle-treated controls (Figure 2.11b).  Moreover, there was a distinct 
change in the morphological appearance of the DAPI-stained (stained blue) 
cells in the eicosanoid-treated slides that failed to incorporate BrdU (Figure 
2.11b). 
 
Figure 2.11. Effect of eicosanoids on cell proliferation of HUVECs.  (a) 
For BrdU ELISA, HUVECs (2000 cells/well) were treated with various doses of 
11-oxo-ETE and 15d-PGJ2 for a period of 24 h. Cell proliferation (means + 
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S.E.M.) was assessed by measuring absorbance at 370 nm and converting it 
to cell numbers using a standard curve and thereby used to construct the 
IC50 plots.  All experiments were conducted three times in triplicate.  
Representative data from one experiment conducted in triplicate are shown 
as means ± S.E.M.  (b) For immunofluorescence, HUVECs (8000/chamber) 
were treated with 2 M of 15d-PGJ2 or 11-oxo-ETE for 24 h and then stained 
for BrdU and counterstained with DAPI (cells stained blue). Photomicrographs 
were taken at x200 magnification, and BrdU-positive (stained purple) cells 
were counted in randomly selected microscopic fields (10/replicate) as 
compared to the total number of cells in these fields.  All experiments were 
conducted in triplicate.  Representative photomicrographs from one set of 
replicates are shown. 
 
2.5 DISCUSSION 
15-PGDH catalyzes NAD+-mediated oxidation of the 15(S)-hydroxyl moiety 
of PGs and other eicosanoids (Figure 2.1) (52, 58, 68). Previous studies had 
established that 15-PGDH is also responsible for metabolizing the 15-LOX-
derived 15(S)-HETE in macrophages and monocytes to 15-oxo-ETE (68). 
Surprisingly, it was found that 11(R)-HETE is also metabolized by 15-PGDH 
to a novel eicosanoid, that was identified as 11-oxo-ETE (Figure 2.3). 
Moreover, the catalytic activity of human 15-PGDH for oxidation of 11(R)-
HETE (Figure 2.3) was very similar to that observed for 15(S)-HETE. These 
results were very surprising in view of the lack of a 15(S)-hydroxyl group on 
11(R)-HETE as well as the incorrect 11(R)-stereochemistry. The structure of 
11-oxo-ETE metabolite was established by chemically synthesizing authentic 
11-oxo-ETE from racemic 11-HETE.  11-Oxo-ETE was formed in both LoVo 
cell lysates (Figure 2.7a) and secreted from intact cells (Figure 2.8a); 
whereas 11-oxo-ETE was not formed by HCA-7 cell lysates (Figure 2.7b) or 
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secreted from intact cells (Figure 2.8b). Since LoVo cells express COX-2 as 
well as 15-PGDH, whereas HCA-7 cells express COX-2 but not 15-PGDH (52, 
70, 71), these data convincingly prove that 11-oxo-ETE is an endogenous 
product formed enzymatically by a combination of COX-2 and 15-PGDH. 
11-oxo-ETE is isomeric with 15-oxo-ETE (Figure 2.2) and also has very 
similar LC properties. Therefore, a reversed phase LC-SRM/MS method was 
developed to separate the un-derivatized oxo-ETEs, and normal phase was 
implemented to separate their PFB derivatives. This made it possible to 
readily analyze the two oxo-ETEs.  Endogenous eicosanoids formed by LoVo 
and HCA-7 epithelial cells and cell lysates as well as those formed after the 
addition of AA were analyzed as PFB derivatives by chiral LC-ECAPCI/MS (72, 
73). Representative chromatograms of the eicosanoids produced 
endogenously in the LoVo cell lysates are shown in Figure 2.6.  Inhibition of 
15-PGDH enzyme by CAY10397 significantly diminished the formation of 
endogenous 11-oxo-ETE in LoVo cell lysates (Figure 2.7a). In addition, the 
formation of 15-oxo-ETE as well as 13,14-dihydro-15-oxo-PGE2, the other 
two 15-PGDH-dependent metabolites, were also significantly reduced in LoVo 
cell lysates treated with CAY10397 (Figure 2.7a). In contrast, the three 15-
PGDH products, namely, 11-, 15-oxo-ETE and 13,14-dihydro-15-oxo-PGE2, 
were undetectable in HCA-7 cells as these cells do not express any 15-PGDH 
(52, 70). Instead, the corresponding precursors for these three metabolites 
were observed in the lysates.  Furthermore, treatment with CAY10397 had 
no effect on levels of 11(R)-HETE, 15(S)-HETE or PGE2 (Figure 2.7b). Intact 
LoVo cells also secreted 11-oxo-ETE, 15-oxo-ETE as well as 13,14-dihydro-
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15-oxo-PGE2. However, the 11-oxo-ETE was cleared very rapidly (Figure 
2.8a), suggesting that further metabolism was occurring.  Subsequently, it 
was observed that 11-oxo-ETE underwent GST-mediated metabolism to 11-
OEG, similar to the formation of 15-OEG in RIES cells (Figure 2.9) (43). 
Moreover, it was observed that 11-oxo-ETE and [13C20]-15-oxo-ETE could be 
converted to 11(S)-HETE and [13C20]-15(S)-HETE in the Caco-2 cell line, 
which does not express 15-PGDH. Therefore, a reductive pathway could be 
responsible for the formation of endogenous 11(S)-HETE. 
11-Oxo-ETE differs from 15d-PGJ2 in the lack of a C-8 to C-12 bond, in 
having a cis-8,9- rather than cis-9,10-double bond, and a cis- rather than 
trans-14,15-double bond (Figure 2.2). This suggested that 11-oxo-ETE might 
be a more effective inhibitor of HUVEC proliferation than 15-oxo-ETE (68) 
with a potency similar to that observed for 15d-PGJ2 (61). In fact, 11-oxo-
ETE was six times more potent than 15-oxo-ETE (data not shown) and 
equipotent with 15d-PGJ2 at inhibition of HUVEC proliferation (Figure 2.10). 
Dose-response studies revealed that its IC50 was 2.1 M compared to an IC50 
value of 2.3 M for 15d-PGJ2 (Figure 2.10a). Moreover, immunofluorescence 
microscopy revealed that 11-oxo-ETE not only inhibited BrdU incorporation 
into the HUVECs but it also caused a dramatic change in the shape and 
morphology of these cells (Figure 2.10b). Although the total number of cells 
counted in the eicosanoid-treated groups were quite similar to the vehicle-
treated group, the BrdU-negative cells were significantly distorted (Figure 
2.10b). Typically, if the cells are undergoing death by apoptosis, they would 
appear more compact and round.  However, 11-oxo-treated cells were 
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elongated and stretched (Figure 2.10b), which could be indicative of 
extensive cytoskeletal remodeling, cell cycle arrest and/or differentiation. 
Interestingly, 11-oxo-ETE formation could not be detected in HUVEC lysate 
that was incubated with 11(R)-HETE (data not shown). Finally, immunoblot 
analysis of HUVEC cell lysate failed to detect COX-2 protein (data not shown). 
Taken together, these data suggest a paracrine role for 11-oxo-ETE on 
endothelial cell proliferation.   
As noted above, inhibition of 15-PGDH resulted in significant decreases in 
11-oxo-ETE formation in LoVo cells (Figure 2.7). 15-PGDH is down-regulated 
in numerous cancers types (49, 52-56), which would cause a decrease in 11-
oxo-ETE biosynthesis by preventing the in vivo conversion of 11(R)-HETE to 
11-oxo-ETE (Figure 2.1). This could be particularly devastating as COX-2 
becomes up-regulated during tumorigenesis, which would result in elevated 
PGE2 biosynthesis along with decreased 15-PGDH-mediated inactivation to 
15-oxo-PGE2 (Figure 2.1). Ultimately, this would result in an increase in 
PGE2-mediated pro-proliferative activity (48,57) without the counter effect of 
anti-proliferative oxo-ETEs. Increased PGE2 activity can also arise through 
down-regulation of the influx PG transporter - the organic anion transporter 
polypeptide (OATP) 2A1 (Figure 2.1) (74,75).  
There is some evidence that 11-oxo-ETE can activate nuclear PPAR.(76) 
PPAR is a ligand-dependent transcription factor responsible for the 
regulation of a number of cellular events ranging from lipid metabolism to 
apoptosis.(77) 15d-PGJ2 is a PPAR agonist, which might account for its 
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ability to inhibit endothelial cell proliferation (60,61). However, this effect is 
only observed with pharmacological amounts of 15d-PGJ2 rather than 
endogenous concentrations (69). Besides PPAR agonistic activity, 15d-PGJ2 
is also known to be an inhibitor of NFB signaling, a pathway critical to cell 
proliferation as well as tumorigenesis (78,79). In view of the ability of COX-
2/15-PGDH to rapidly metabolize AA to nM amounts of oxo-ETEs, together 
with the structural similarity of oxo-ETEs and 15d-PGJ2 (Figure 2.2), it will be 
important to determine which of these activities are shared by both classes 
of eicosanoids. It is noteworthy that docosahexaenoic acid and 
docosapentaenoic acid can be metabolized by the sequential action of COX-2 
and dehydrogenises into oxo-eicosanoids that modulate the antioxidant 
response (21). Similarly 5-LOX-drived 5(S)-HETE is metabolized by 5-
hydroxyeicosanoid dehydrogenase into the chemoattractant 5-oxo-ETE (80). 
Therefore, the oxo-eicosanoids represent a family of oxidized lipids with 
diverse biological activities. 
In summary, these studies have revealed that down-regulation of 15-PGDH 
inhibits the formation of the endogenous anti-proliferative eicosanoid, 11-
oxo-ETE. Therefore, 15-PGDH has two quite distinct properties; it can either 
inactivate PGs or activate HETEs to oxo-ETEs that exert a paracrine effect on 
endothelial cells (Figure 2.1).  11-Oxo-ETE, a member of the oxo-ETE family 
(80-82), was observed previously as an endogenously-derived lipid in human 
atherosclerotic plaques (83). However, the biosynthesis of 11-oxo-ETE and 
its biological activity were not evaluated in that study. Furthermore, there 
does not appear to be any subsequent report of its formation either, in vitro 
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or in vivo. In fact 11-oxo-ETE is derived from COX-2/15-PGDH-mediated AA 
metabolism and it inhibits endothelial cell proliferation with an IC50 that is 
very similar to that of 15d-PGJ2. 
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Chapter 3   Cyclooxygenase-2-mediated reactive 
aldehyde formation 
 
3.1 ABSTRACT 
HNE and ONE are major products of lipid. These bifunctional electrophiles 
have many biological effects, which is probably due in part to their high 
reactivity with endogenous nucleophiles, such as glutathione, proteins and 
DNA. HNE has a chiral center at C4. Some recent research has revealed that 
the chirality of HNE is significant since its two enantiomers differ in their 
ability to damage proteins and undergo detoxification. Thus, it is important to 
study the formation of HNE with respect to chirality. In order to accomplish 
this goal, HNE was analyzed as its GSH-adduct form, which allowed increased 
detection sensitivity. It was found that in the presence of GSH, PGG2 and 
15(S)-HPETE mainly produced 4(S)-HNE-GSH. In contrast 11(R)-HPETE 
produced racemic HNE-GSH while 15(R)-HPETE produced 4(R)-HNE-GSH. 
This new finding that HNE formed from different lipid hydroperoxides 
possessing different chiral characteristics suggested a new decomposition 
mechanism for lipid hydroperoxides. Interestingly, it was observed that 4(S)-
HNE-GSH was the predominant isomer arising from incubations of 
recombinant COX-2 with AA in the presence of GSH. However, with aspirin-
modified COX-2, 4(R)-HNE-GSH was the major product.  This observation is 
in keeping with the known activity of aspirin, which converts COX-2 into a 
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15(R)-LOX and produces mainly 15(R)-HPETE. Human colorectal 
adenocarcinoma (LoVo) epithelial cells, which over-expressed COX-2, also 
mainly generated 4(S)-HNE-GSH (86%) in the cell lysate when they were 
treated with AA. This result together with the eicosanoid quantification assay 
showed that in LoVo cells, HNE and ONE were formed mainly from PGG2 and 
not from the HPETEs as has been previously thought. ONE formed on nuclear 
membranes can covalently modify DNA due to its close proximity, resulting in 
mutagenic DNA adducts, such as heptano-etheno-2’-deoxyguanosine (H-
dGuo). 
 
3.2 INTRODUCTION 
PGG2 (Figure 1.1) has been implicated in many inflammatory diseases, since 
PGG2 is the precursor of pro-inflammatory prostaglandins. However, before 
PGG2 is converted to PGH2, PGE2 and other PGs, it could also undergo 
decomposition to malondialdehyde (MDA), together with HNE, and ONE have 
been characterized as cytotoxic and genotoxic lipid peroxidation products 
(32). MDA forms Schiff-base adducts with proteins or DNA bases, while HNE 
and ONE form adducts through Michael addition (32). When MDA is at 
physiological pH, it exists mainly in the enolate form, which has lower 
reactivity compared to HNE and ONE. HNE formation has been implicated as 
a reactive intermediate in many diseases, such as atherosclerosis, 
Alzheimer’s disease, diabetes and Parkinson’s disease (84-86). HNE has one 
chiral center and different strategies have been applied to study HNE 
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enantiomers, including chiral LC-UV, LC-MS, NMR, fluorescence, as well as 
anti-HNE antibody methods (87-91). The Uchida group has studied the 
nature of HNE enantiomers selectively and differentially binding to proteins 
(91, 92), while the Picklo group showed that HNE detoxification by GST or 
AKR is also stereoselective (93, 94). Furthermore, the Brash group has 
demonstrated that 4(S)-HNE is formed with high enantioselectivity from the 
decomposition of 15(S)-HPETE (89). It was established that in LoVo cells, 
PGs were the major COX-2 mediated arachidonic acid metabolites (95). 
Therefore, this provided an excellent model system to examine the 
mechanism of formation of COX-2-derived HNE (Figure 1.1) and ONE. This 
would then make it possible to definitively identify the source of ONE-derived 
DNA-adducts such as H-dGuo.  
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Figure 3.1 Structures of PGE2, HNE-oxime, HNE-GSH-adducts and H-
dGuo. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. The proposed mechanism of the transformation of PGG2 
into HNE and ONE. There might be an intermediate hydroperoxide, 12(S)-
HPTrE, which is formed together with MDA from PGG2 decomposition. The 
hydrogen attached to C7 is abstracted, followed by the formation of a 
carbon-centered radical at C7, and then the double bond between C8 and C9 
relocates to C7 and C8, together with the relocation of C7 radical to C9 
radical. A hydroperoxide radical is formed after an oxygen molecule radical to 
C9 radical. A hydroperoxide radical is formed after an oxygen molecule 
inserts to C9 position, followed by hock rearrangement and the formation of 
4(S)-HPNE. The 4(S)-HPNE is then converted to 4(S)-HNE and ONE. 
 
3.3 EXPERIMENTAL PROCEDURES 
3.3.1 Chemicals and Reagents.  
AA (peroxide-free), 11(R,S)-HETE, 15(R,S)-HETE, [2H8]-15(S)-HETE, [
2H8]-
12(S)-HETE, 12(S)-HHT, PGE2, [
2H4]-PGE2, PGF2α, [
2H4]-PGF2α, [
2H3]-4-HNE,  
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PGG2, protease inhibitor cocktail (100X), recombinant ovine COX-1 and 
human COX-2 were purchased from Cayman (Ann Harbor, MI). 2,3,4,5,6-
pentafluorobenzyl (PFB) bromide, Trizma-HCl, ethacrynic acid, hematin 
porcine, hydroxylamine hydrochloride, L-glutathione, phenol, L-ascorbic acid, 
zopolrestat, 2’-deoxyguanosine monohydrate and lipoxidase from Glycine 
max (soybean) were purchased from Sigma-Aldrich (St. Louis, MO). 
Rofecoxib was purchased from Sequoia Research Products (UK). Fetal bovine 
serum (FBS) was from Gemini Bioproducts (West Sacramento, CA). F12K 
medium, D-glucose, L-glutamine, penicillin, and streptomycin were supplied 
by Invitrogen (Carlsbad, CA). LC-MS grade water, hexane, methanol, 
isopropanol, acetonitrile and dichloromethane were obtained from Fisher 
Scientific (Pittsburgh, PA). Gases were supplied by The Linde Group (Munich, 
Germany).   
3.3.2 Cell Culture.   
LoVo cells (ATCC, Manassas, VA) were cultured in F12K medium 
supplemented with 10% FBS, 2 mM L-glutamine, 100,000 units/l penicillin 
and 100 mg/l streptomycin.   
3.3.3 MS conditions.  
A triple stage quadrupole (TSQ Quantum) mass spectrometer (Thermo 
Electron, San Jose, CA) equipped with an APCI source was used for the 
quantitative lipidomics analyses. Targeted chiral LC-ECAPCI/SRM/MS analysis 
was conducted using PFB derivatives of 7 lipids and 4 heavy isotope analog 
internal standards. For the lipidomics profile, the instrument was operated in 
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the negative ion mode, and unit resolution was maintained for both precursor 
and fragment ions. Operating conditions for the TSQ Quantum were: 
vaporizer temperature at 450°C; heated capillary temperature at 250 °C with 
the corona discharge needle set at 30 µA; nitrogen as sheath (25 psi) and 
auxiliary (5 arbitrary units) gas. Collision-induced dissociation (CID) was 
performed using argon as the collision gas at 1.5 mtorr in the RF-only 
quadrupole. The following SRM transitions were used: 11(R)-HETE-PFB, m/z 
319 → 167 (CE, 16 eV), 15-HETE-PFB, m/z 327 → 226 (CE, 13 eV), 12(S)-
HHT-PFB, m/z 279 → 217 (CE, 18 eV), [2H8]-15(S)-HETE-PFB, m/z 327 → 
226 (CE, 13 eV), [2H8]-12(S)-HETE-PFB, m/z 327 → 184(CE, 14 eV), PGE2-
PFB, m/z 351 → 271 (CE, 18 eV), [2H4]-PGE2-PFB, m/z 355 → 275 (CE, 18 
eV), PGD2-PFB, m/z 351 → 271 (CE, 18 eV), [
2H4]-PGD2-PFB, m/z 355 → 275 
(CE, 18 eV), PGF2α-PFB, m/z 353→ 193 (CE, 25 eV), [
2H4]- PGF2α-PFB, m/z 
357→ 197(CE, 25 eV). 
For oxime derivatives analysis, the Finnigan LTQ mass spectrometer (Thermo 
Electron, San Jose, CA) was used in the positive ion mode with an 
electrospray ionization (ESI) source. The operating conditions were: spray 
voltage at 4 kV; capillary temperature at 250 °C; capillary voltage at 35 V; 
nitrogen as sheath (40 psi) and auxiliary (20 arbitrary units) gas. CID was 
performed using helium as the collision gas in the ion trap. The following 
SRM transition (m/z 188 → 154) was monitored for HPNE-oxime (normalized 
CE, 25 %), and SRM transition (m/z 172 → 99) was monitored for HNE-
oxime (normalized CE, 25%).  
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For GSH adduct analysis, the TSQ Quantum was operated in the positive ion 
mode with an ESI source. The operating conditions were: spray voltage at 4 
kV; capillary temperature at 350°C; nitrogen as sheath (35 psi) and auxiliary 
(13 arbitrary units) gas. CID was performed using argon as the collision gas 
at 1.5 mtorr in the Rf-only quadrupole. The following SRM transition (m/z 
464 → 308) was monitored for HNE-GSH (CE, 14 eV).  
For H-εdGuo analysis, the TSQ Quantum was operated in the positive ion 
mode with an ESI source. The operating conditions were: spray voltage at 4 
kV; capillary temperature at 320°C; nitrogen as sheath (25 psi) and auxiliary 
(10 arbitrary units) gas. CID was performed using argon as the collision gas 
at 1.5 mtorr in the Rf-only quadrupole. The following SRM transition (m/z 
404 → 288) was monitored for H-εdGuo (CE, 18 eV).  
3.3.4 LC methods.  
LC separations were conducted using a Waters Alliance 2690 HPLC system 
(Waters Corp., Milford, MA, USA). A Chiralpak AD-H column (250 × 4.6 mm 
inner diameter, 5 µm; Daicel Chemical Industries, Ltd., Tokyo, Japan) was 
employed for normal phase separation (flow-rate 1 ml/min) of PFB-
derivatives of eicosanoids. Gradient 1 was used for separating PFB-
derivatives of HETEs and PGE2. For gradient 1, solvent A was hexane, and 
solvent B was methanol/isopropanol (1:1; v/v). Gradient 1 was as follows: 2% 
B at 0 min, 2% B at 3 min, 3.6% B at 11 min, 8% B at 15 min, 8% B at 27 
min, 50% B at 30 min, 50% at 35 min, and 2% B at 37 min.  Separations 
were performed at 30 °C using a linear gradient.  
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A Chiralpak AD-RH column (150 × 4.6 mm inner diameter, 5 µm; Daicel 
Chemical Industries, Ltd., Tokyo, Japan) on Waters Alliance 2690 HPLC was 
used for reverse phase (isocratic method 1, flow-rate 0.5 ml/min) separation 
of the HNE and HPNE oxime derivatives. The mobile phase for isocratic 
separations was methanol/water (85:15; v/v) with 0.1% formic acid. 4(R,S)-
HNE was separated on the same column connected to Hitachi L-6200 LC with 
mobile phase of methanol/water (85:15, v/v), and the UV absorbance was 
set at 236 nm with L-4000 UV detector (isocratic method 2). For 4(R,S)-
HPNE, the mobile phase was methanol/water (78:12, v/v, isocratic method 
3). Separations were performed at room temperature. 
Chemically synthesized Me-15(S)-HPETE was purified by normal-phase 
(isocratic method 4) preparative LC (Ultrasphere™ 250 × 10 mm, inner 
diameter, 5 µm; Beckman) using Hitachi LC system by monitoring the UV 
absorbance at 236 nm. The mobile phase for isocratic method 2 was 
hexane/isopropanol (197:3, v/v) containing 0.1% acetic acid.   
Chemically synthesized Me-15(R)-HPETE was purified by normal-phase 
(isocratic method 5) LC (Chiralpak AD-H 250 × 4.6 mm, inner diameter, 5 
µm) using Hitachi LC system by monitoring the UV absorbance at 236 nm. 
The mobile phase for isocratic method 4 (flow-rate 1 ml/min) was 
hexane/ethanol (100:2; v/v). The separation was performed at ambient 
temperature using a linear gradient. 
GSH adducts were separated by reversed phase using gradient 2 on Waters 
Alliance 2690 HPLC system. The separation employed a Phenomenex Synergi 
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Hydro-RP column (150 × 4.6 mm inner diameters, 5 µm). Solvent A was 0.1% 
aqueous formic acid, and solvent B was methanol/acetonitrile/formic acid 
(50:50:0.1; v/v). Gradient 2 was as follows: 2% B at 0 min, 12% B at 14 
min, 30% B at 20 min, 42% B at 21 min, 65% B at 27 min, 80% B at 29 min, 
90% B at 33 min, 90% B at 34 min, 2% B at 35 min. The flow rate was 0.4 
ml/min.  The separation was performed at ambient temperature using a 
linear gradient. 
H-dGuo was separated by reversed phase using gradient 3 on Waters 
Alliance 2690 HPLC system. The column used was Phenomenex Kinetex C18 
(100 × 2.1 mm inner diameters, 2.6 µm). Solvent A was 0.1 % aqueous 
formic acid, and solvent B was acetonitrile/formic acid (100:0.1; v/v). 
Gradient 3 was as follows: 10% B at 0 min, 10% B at 3 min, 30% B at 3.5 
min, 90% B at 15 min, 90%B at 22 min, 10% B at 23 min. The flow rate was 
0.2 ml/min. The separation was performed at ambient temperature using a 
linear gradient. 
3.3.5 Chirality of HNE-GSH adduct formed from eicosanoids.  
HPETEs or PGG2 (1.7 µM) were incubated at 37
 oC with hematin (100 nM) and 
GSH (4 mM) in 200 µl 100 mM Tris-Cl (pH 7.9) for 30 min, and reaction 
mixtures were loaded onto SPE column (oasis HLB, 30 mg) pre-conditioned 
with methanol and then 0.1% formic acid. The column was washed with 1 ml 
water and eluted with 250 µl methanol, and then 20 µl was analyzed by 
reverse phase LC-ESI/MS using gradient 2, as described above. Each sample 
was prepared in triplicate. 
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3.3.6 Formation of the ONE dGuo adduct (H-dGuo) from PGG2.  
PGG2 or 15(S)-HPETE (15 µM) in 200 µl Chelex-treated 100 mM MOPS 
buffer(pH 7.2), containing 150 mM NaCl was incubated with 100 µM 
NH4Fe(SO4)2 and 100 µM dGuo at 37 °C for 24 hrs. Ethyl acetate (2 × 800 µl) 
was added to extract products. Organic layer was evaporated and dissolved 
to 100 µl MeOH/H2O (1:9; v/v). 20 µl of each sample was injected to LC-
ESI/MS (gradient 3).  
3.3.7 Kinetic study of AA metabolism by COX.  
6.7 nM recombinant ovine COX-1 or 14 nM recombinant human COX-2 was 
pre-incubated with cofactor hematin (100 nM), phenol (1 mM) and GSH (4 
mM) in 100 mM Tris-Cl (pH 7.9) for 60 sec at 37oC before adding various 
concentrations of AA (0, 2.5 M, 5 M, 10 M, 20 M and 50 M). Each total 
reaction volume was 200 l.  In separate experiments, the formation of 
eicosanoids was found to be linear for the first 45 sec. After 30 sec 
incubation, the enzymatic reaction was quenched by adding 400 l of ice-cold 
methanol and strong vortex. 20 µl 10% aqueous acetic acid was added to 
adjust pH to 3-4, together with 20 µl internal standards mixture (50 pg/ µl 
[2H8]-15(S)-HETE, [
2H8]-12(S)-HETE, [
2H4]-PGE2 and [
2H4]-PGF2α). The 
control samples were prepared by incubating same concentrations of AA with 
denatured COX for 30 sec in the same buffer as above. Eicosanoids were 
extracted with 1.2 ml of dichloromethane/methanol (8:1; v/v). The lower 
organic layer was then evaporated to dryness under nitrogen and 
reconstituted in acetonitrile (100 l). PFB derivatives were synthesized as 
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described above and analyzed by normal phase LC-ECAPCI/MS. Here, 
hematin stock solution (1mM in 0.1N NaOH) was prepared weekly, while 
phenol and GSH solutions were freshly prepared.  
Eicosanoids were quantified by interpolation from a standard curve prepared 
with 15-HETE, 11-HETE, 12(S)-HHT, PGE2 and PGF2α using [
2H8]-15(S)-HETE, 
[2H8]-12(S)-HETE, [
2H4]-PGE2, and [
2H4]-PGF2α as the internal standard. 
Samples were prepared in duplicate. 
3.3.8 Eicosanoids profile of AA metabolism by COX.  
Recombinant ovine COX-1 or human COX-2 (25 nM) was incubated with 5 µM 
AA in 200 µl 100 mM Tris-Cl buffer (pH 7.9), containing 1 µM hematin, 1 mM 
phenol and 4 mM GSH. The incubation was kept at 37 °C for 30 min, and 
then the reaction mixtures were added with internal standards (50 pg/ µl 
[2H8]-15(S)-HETE, [
2H4]-PGE2 and [
2H4]-PGF2α. The products were extracted 
with diethyl ether (2×600 µl) at pH 3-4. The organic layer was evaporated in 
N2 flow and PFB derivatives were made before analysis by LC-ECAPCI /MS. 
3.3.9 Standard curves for eicosanoid quantification.  
To quantify eicosanoids from COX mediated AA metabolism, Eppendorf tubes 
containing 0.2 ml 100 mM Tris-Cl (pH 7.9) were spiked with lipid standards, 
together with internal standards for ([2H8]-15(S)-HETE , [
2H8]-12(S)-HETE, 
[2H4]-PGE2 and [
2H4]-PGF2α, 1 ng each). The extraction and PFB derivatization 
methods are the same as mentioned above. Each sample was prepared in 
duplicate. 
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3.3.10 Chirality of HNE-GSH formed from COX mediated AA 
metabolism.  
25 nM COX-1 or COX-2 were incubated with 5 µM AA in 100 mM Tris-Cl (pH 
7.9) in the presence of hematin (1 µM), phenol (1mM), and GSH (4mM). The 
total volume reaction mixture volume was 200 µl. Here, arachidonic acid (10 
µM) was pre-incubated with Girard T reagent (30 mM) in Tris-Cl buffer with 5% 
acetic acid for 20 min at R.T. Then 2 volume of hexane was added to extract 
arachidonic acid. Hexane layer was transfer to a separate tube, and 
evaporated in N2 flow, and then re-dissolved to Tris-Cl buffer before adding 
to reaction mixture. After 30 min, the reaction mixtures were then acidified 
with 10% aqueous acetic acid (10 µl) to pH 3-4, followed by addition of the 
internal standard mix,  [2H3]-HNE-GSH (5 pg/µl, 20 µl). Samples were 
centrifuged at 13500 rpm for 2 min. The supernatant was purified by SPE 
cartridge and analyzed by LC-ESI/MS, as described above. Samples were 
prepared in triplicate. Here, [2H3]-HNE-GSH was prepared by incubating 4-
(S)-HNE and 4-(R)-HNE with GSH, respectively. 4(S)-HNE and 4-(R)-HNE 
were as described previously (89), using isocratic method 2. 
3.3.11 Standard curves for HNE-GSH quantification.  
To quantify HNE-GSH adduct from COX-mediated AA metabolism, standard 
HNE (0.01, 0.1,0.5,2 and 10 ng) was incubated with GSH (4 mM) at 37 ºC 
for 30 min, and then [2H3]-HNE-GSH (5 pg/µl, 20 µl) was added to reaction 
mixtures. The reaction mixtures were purified by SPE cartridge and analyzed 
by LC-ESI/MS as previously described. 
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3.3.12 Chirality of HNE-GSH formed from LoVo cell lysate.  
LoVo cells were grown to 90% confluence, washed with phosphate-buffered 
saline (PBS) buffer (2×10ml), and then gently scraped in 400 µl of lysis 
buffer containing 100 mM Tris-HCl (pH 7.9), protease inhibitor (diluted from 
100X), GSH (4 mM), GST inhibitor ethacrynic acid (20 µM) and AKR inhibitor 
zopolrestat (50 nM). Cell suspension was transferred to 2 ml Eppendorf tubes, 
and sonicated for 60 seconds on ice (power 5). Cell lysate was then 
incubated for 15 min at 37°C. The pH was then adjusted to 3 to 4 with 10% 
aqueous acetic acid (10 µl) followed by addition of the internal standard mix, 
[2H3]-HNE-GSH (5 pg/µl, 20 µl). Samples were centrifuged at 13500 rpm for 
2 min, and the supernatant was purified by SPE cartridge. The cartridge was 
eluted with 250 µl methanol, and 40 µl was analyzed by LC-ESI/MS. For the 
control samples, LoVo cells were pretreated with rofecoxib (50 M) in F-12K 
medium at 37°C for 2 hrs to inhibit COX-2 activity, and then cell lysate was 
prepared as described above. To quantify eicosanoids formation under this 
condition, a separate set of samples were prepared, and the lipid extraction 
and PFB derivatization methods described previously were used. 
3.3.13 Methylation of 15(S)-HPETE. 
Ethereal diazomethane (CH2N2) was freshly prepared by reacting N-methyl-
N-nitroso-p-toluensulfonamide with sodium hydroxide, employing a 
diazomethane generator from Wheaton (Millville, NJ). The manufacturer’s 
procedures were followed, and the product was confirmed by both LC-MS and 
NMR. 
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3.3.14  Chemical synthesis and purification of 15(R)-HPETE methyl 
ester. 
15(R)-HPETE methyl ester was synthesized according to Corey’s method 
(104, 105). Racemic 15-HPETE methyl ester was prepared by converting 
15(S)-HETE methyl ester to the mesylate derivative, which was then treated 
with hydrogen peroxide in ether at -110 °C. 15(R)-HPETE methyl ester was 
isolated by normal phase-HPLC using isocratic method 5. 
3.3.15  Separation and hydroxylamine derivatization of 4(S)-HPNE.  
4(R,S)-HPNE from Cayman was separated by Chiralpak AD-RH column, as 
described previously (isocratic method 3). The first peak of the two 
enantiomers was collected and evaporated in N2 flow, and then it was 
dissolved into 200 µl Chelex-treated MOPS buffer (100 mM, pH 7.2), 
containing 150 mM NaCl, followed by the addition of 1 mg hydroxylamine 
hydrochloride. The mixture was incubated at 37 ºC for 1 h before extraction 
with ethyl acetate (2 × 800 l). The organic layer was evaporated in N2 flow, 
and then dissolved to 100 l MeOH. 10 l was analyzed by LC-LTQ/MS, as 
described above. The rest of the solution was added with 0.4 mg SnCl2 and 
stayed at room temperature for 30 min. Water (900 l) was added and then 
3 ml ethyl acetate, and the mixture was centrifuged at 3000 rpm for 5 min. 
Then the ethyl acetate was evaporated and dissolved to 100 l MeOH/water 
(85:15; v/v), and 10 µl was injected to LC-ESI/SRM/MS (isocratic method 1). 
4(S)-HNE isolated from 4(R,S)-HNE (89) was also converted to the oxime 
derivative under the same condition as used for HPNE. By comparison of 
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4(S)-HNE oxime peak from standard 4(S)-HNE with that obtained from the 
reduction of HPNE-oxime, it was possible to conclude that the first peak, 
which eluted from the AD-RH column was 4(S)-HPNE. 
3.3.16 Conversion of 4(S)-HPNE-oxime to 4(S)-HNE-oxime in the 
presence of Vit C.  
4(S)-HPNE-oxime prepared as described above was separated with an AD-RH 
column using isocratic method 1. The two isomer peaks were collected 
separately, and then incubated 200 µl Chelex-treated MOPS buffer (100 mM, 
pH 7.2), containing 150 mM NaCl and 1 mM Vit C, 37 ºC for 30 min. A similar 
ethyl acetate extraction workup was applied to purify the products. The 
samples were analyzed with the same LC-MS method as 4(S)-HNE-oxime. 
 
3.4 RESULTS 
3.4.1 Chirality of HNE-GSH formed from eicosanoids.   
HNE was converted to its GSH-adduct in order to increase the sensitivity of 
detection.  GSH also introduced new chiral centers, so the GSH-adduct 
diastereomer formed from 4(S)-HNE and the one formed from 4(R)-HNE 
could be readily separated with a non-chiral column. PGG2, 11(R)-HPETE, 
15(S)-HPETE, and 15(R)-HPETE-Me (1.7 µM) were incubated with hematin 
and GSH, resulting in the formation of different HNE-GSH diastereomers that 
could be readily analyzed. A representative chromatogram (Figure 3.3) 
reveals the separation of R-HNE-GSH (retention time 24.4 and 25.8 min) and 
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S-HNE-GSH (retention time 24.9 min). 11(R)-HPETE gave racemic HNE-GSH. 
15(S)-HPETE gave (S)-HNE-GSH, while 15(R)-HPETE-Me gave (R)-HNE-GSH. 
PGG2 only gave (S)-HNE-GSH.  
 
Figure 3.3. The chirality of HNE formed from eicosanoids. Figure (a), 
(b), (c) (d) show the chromatography of HNE-GSH formed from 15(S)-HPETE, 
15(R)-HPETE methyl ester, 11(R)-HPETE and PGG2, respectively. (e) is the 
chromatography of 4(R,S) HNE and GSH adduct standard. HNE-GSH is 
separated by reverse phase LC, and monitored by SRM transition m/z 464 to 
308. The middle peak is 4(S)-HNE and GSH adduct. There are two peaks (the 
first and the third) corresponding to GSH adduct with 4(R)-HNE. This is 
because there are multiple chiral centers in HNE-GSH adducts. 
 
3.4.2 Formation of H-εdGuo from PGG2.  
PGG2 was incubated with dGuo in the absence or presence of Fe(II). PGG2 
decomposed to ONE in the presence of Fe(II) and ONE was trapped by dGuo 
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to form H-εdGuo. After 24 h incubation, the product was extracted with ethyl 
acetate. The organic layer was evaporated and dissolved into starting mobile 
phase. Samples were analyzed in LC-ESI/MS. The retention time of H-εdGuo 
is 14.7 min, as shown in Figure 3.4. 
 
Figure 3.4. The formation of H-dGuo from PGG2 and 15(S)-HPETE. 
Samples were prepared from 15 µM PGG2 or 15(S)-HPETE in Chelex-treated 
100mM MOPS buffer, containing 150 mM NaCl buffer (pH 7.2) in the 
presence of 100 µM dGuo and in the presence or absence of 100 µM Fe(II) at 
37 °C for 24 hr. Figure (a) and (b) show the H-dGuo formation from PGG2 in 
the absence and presence of FeII, respectively. Figure (c) and (d) show the 
H-dGuo formation from 15(S)-HPETE in the absence and presence of Fe, 
respectively. Reverse phase LC coupled with SRM transition m/z 404 to 288 
(collision energy 18 eV) was used to detect H-dGuo.  
3.4.3 Kinetic study of AA metabolism by COXs.  
Various concentrations of AA were incubated with recombinant ovine COX-1 
and human COX-2 at 37 °C. A Michaelis-Menten kinetic analysis of 
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eicosanoids formation revealed that the Vmax values for conversion of AA to 
PGE2, 11(R)-HETE, 15(S)-HETE, and 15(R)-HETE by COX-1 are 25.16, 13.86, 
13.83, and 3.856 pmol/min, respectively, while Km values are 3.768, 9.434, 
19.76, and 8.334 µM, respectively, and the corresponding kcat values are 
18.78, 10.34, 10.32, and 2.878 min-1, respectively (Figure 3.5, Table 3.1).  
 
Table 3.1.  The Km, Vmax, kcat and kcat/Km values of COX substrate AA 
with the respect of different products. 
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Figure 3.5. The saturation curves for recombinant ovine COX-1 and 
human COX-2 with AA as the substrate. All of the samples were prepared 
in duplicate (means ± S.E.M.) 
 
3.4.4 Eicosanoid profile of AA metabolism by COX.  
Recombinant ovine COX-1 or human COX-2 (25 nM) was incubated with 5 µM 
AA in 200 µl 100 mM  Tris-Cl buffer (pH 7.9), containing 1 µM hematin, 1 mM 
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phenol and 4 mM GSH. The incubation was kept at 37 °C for 30 min, and 
then the reaction mixtures were added with internal standards (50 pg/ µl 
[2H8]-15(S)-HETE, [
2H4]-PGE2 and [
2H4]-PGF2α). The products were extracted 
with diethyl ether (2 × 600 µl) at pH 3-4. The organic layer was evaporated 
in N2 flow and PFB derivatives were made for LC-ECAPCI /MS analysis. The 
results are shown in Figure 3.6. If PGE2, PGF2 and 12-HHT are used to 
reflect the original PGG2 level, and15-HPETE and 11-HPETE to reflect the LOX 
activity, then the PG pathway comprises > 88 % of the total COX-1 
metabolites, and > 86 % for the COX-2 enzyme metabolites. The eicosanoids 
formation from LoVo cell lysate were extracted and quantified following a 
similar procedure. Figure 3.9 shows the products profiles from LoVo cell 
lysate. The product distribution was similar to that obtained from 
recombinant COX-2. PG metabolites comprised > 82 % of the overall 
eicosanoids, which indicates the initially formed PGG2 was the major COX-2-
derived metabolite.  
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Figure 3.6. Eicosanoids formed from recombinant ovine COX-1 and 
human COX-2. Data is performed in triplicate (means ± S.E.M.) 
 
3.4.5 Chirality of HNE-GSH formed from COX-mediated AA 
metabolism. 
The HNE-GSH-adducts from 25 nM COX-1 or COX-2 incubation with 5 µM AA 
were purified by SPE and then analyzed by LC-ESI/SRM/MS. A representative 
chromatogram (Figure 3.7) reveals the separation of R-HNE-GSH (retention 
time 24.4 and 25.8 min) and S-HNE-GSH (retention time 24.9 min). A 
summary of the R, S percentage of HNE from different precursors is shown in 
Table 3.2. 
 
 
85 
 
Figure 3.7. Chirality character of HNE-GSH formed from COX 
mediated AA metabolism Figure (a) shows HNE-GSH formed from COX-1 
mediated AA metabolism, while HNE-GSH in Figure (b) comes from COX-2. 
[2H3]-HNE-GSH in Figure (c) is racemic internal standard, which is monitored 
by SRM transition m/z 467 to 308.  
 
Substrates  4(R)-HNE(%)  4(S)-HNE(%)  
11(R)-HPETE 
15(S)-HPETE 
15(R)-HPETE 
COX-1 + AA 
COX-2 + AA 
PGG2  
52.0 
7.0 
94.0 
6.3 
8.5 
11.0  
48.0 
93.0 
6.0 
93.7 
91.5 
89.0  
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Table 3.2 The chirality of HNE-GSH-adducts formed from different 
hydroperoxides and COX-mediated AA metabolism 
   
3.4.6 Chirality of HNE-GSH-adducts formed from LoVo cell lysate.  
LoVo cells are known to express COX-2. This was confirmed by Western blot 
analysis (data not shown).  LoVo cell lysates were incubated with 100 mM 
Tris-Cl (pH 7.9), protease inhibitor, GSH (4 mM), GST inhibitor ethacrynic 
acid (20 µM) AKR inhibitor zopolrestat (50 nM). [2H3]-HNE (5 nM) or AA (20 
µM) was added and incubation was kept for 15 min. Inhibition of GST 
abolished the effect of GST on enantioselective HNE-GSH-adduct formation. 
The AKR1B inhibitor stabilized HNE-GSH.(23) Racemic [2H3]-HNE was added 
to the lysate mixture, and racemic [2H3]-HNE-GSH was obtained (Figure 
3.8c), which indicated that under this condition, the chirality of HNE-GSH 
from LoVo cell lysate supplemented with AA would represent the chirality of 
HNE formed from LoVo cell lysate (Figure 3.8b). Mainly, the S-HNE-GSH-
adduct was detected, which was consistent with the chiral analysis of 
eicosanoids from LoVo cell lysates (Figure 3.9). Pre-treatment of rofecoxib 
inhibited > 90% of PGE2 formation, so rofecoxib-treated LoVo cell lysate was 
used to provide a control sample. 
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Figure 3.8. The formation of 4(S)-HNE and GSH adduct from LoVo cell 
lysate. Figure (a) displays HNE-GSH adduct from rofecoxib-treated LoVo cell 
lysate, which is used to represent the basal level of HNE-GSH adduct. Figure 
(b) shows HNE-GSH formed from LoVo cell lysate in the presence of 
ethacrynic acid, zopolrestat, and GSH Figure (c) is the formation of [2H3]-
HNE-GSH after adding 250 pg [2H3]-HNE to LoVo cell lysate. All of these 
experiments were done in triplicate, and this Figure reflects one of the 
triplicates. 
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Figure 3.9. Eicosanoids formed from LoVo cell lysate in the presence 
of ethacrynic acid, ispolrestat, and GSH. All of the samples were 
prepared in triplicate. As shown above, PGE2 was the major metabolite. 50 
µM rofecoxib almost abolished the formation of eicosanoids from COX-2. All 
of these experiments were performed in triplicate (means ± S.E.M.). 
 
3.4.7 Separation and oxime derivatization of 4(R,S)-HNE and 4(R,S)-
HPNE 
Both HNE and HPNE enantiomers could be separated on the same column, 
although the separation of 4(R,S)-HNE was more efficient(see Figure 3.10). A 
previous study had established that under these LC conditions, 4(S)-HNE is 
eluted first (7.6 min) followed by 4(R)-HNE. In order to confirm the chirality 
of the two HPNE enantiomers, the first eluting peak was collected and 
reacted with hydroxylamine in 200 l 100 mM MOPS buffer with 150 mM 
NaCl, pH7.2. The resulting oxime was extracted with ethyl acetate (800 l, 
twice), and the organic layer was evaporated under N2. The HPNE-oxime was 
then re-dissolved into 100 l methanol and 10 l was then analyzed by LC-
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MS on the LTQ instrument. It was also was reduced to HNE-oxime by adding 
SnCl2, and the mixture was incubated at room temperature for 30 min. The 
product was again extracted with ethyl acetate. HNE-oxime formed from 
HPNE-oxime reduction was analyzed by the same LC-MS method. Figure 3.10 
shows that the first peak (15.2 min) collected from 4(R,S)-HPNE was reduced 
to 4(S)-HNE only. The SnCl2 reduction did not change the chirality of 
hydroperoxy group, so the 15.2 min peak corresponded to 4(S)-HPNE, while 
the 16.2 min peak was 4(S)-HPNE. 
 
 
 
 
 
 
 
 
 
 
4(S)-HPNE 
4(S)-HPNE 
4(S)-HNE 
4(R)-
HNE 
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Figure 3.10. Chiral LC separation of 4(R,S)-HPNE and 4(R,S)-HNE and 
Chiral LC-MS analysis of their corresponding oxime derivatives. 
 
Based on the data shown in Figure 3.10, the first peak eluted from AD-RH 
column using 78% MeOH/water as the mobile phase corresponded to 4(S)-
HPNE. In the presence of Vit C, the 4(S)-HPNE could be converted to 4(S)-
HNE without changing the chiral center at C4. Thus, monitoring the chirality 
of HNE would reflect the chiral character of HPNE. 
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Figure 3.11 The conversion of 4(S)-HPNE-oxime to 4(S)-HNE-oxime 
in the presence of Vit C. Figure (a) shows 4(S)-HPNE-oxime (syn- and 
anti-isomers). Figure (b) is 4(S)-HNE-oxime isomer1 formed from 4(S)-
HPNE-oxime isomer1, while (c) is 4(S)-HNE-oxime isomer 2 formed from 
4(S)-HPNE-oxime isomer2. Figure (d) shows the two isomers from standard 
4(S)-HNE-oxime. The 4(R,S)-HPNE and 4(R,S)-HNE enantiomers are 
separated by chiral AD-RH column. HPNE-oxime is monitored by SRM 
transition m/z 188 to 154 at collision energy 25%, while HNE-oxime was 
monitored by the SRM transition m/z 172 to 99 at the same collision energy. 
 
3.4.8  Chemical synthesis and purification of 15(R)-HPETE methyl 
ester. 
The synthesis of 15(R)-HPETE methyl ester was achieved by converting 
15(S)-HETE methyl ester to racemic 15-HETE methyl ester. 15(S)-HPETE was 
prepared by oxidation of arachidonic acid from LO, and then methylated by 
CH2N2. The reduction of the hydroperoxy group at C15 to alcohol was via 
NaBH4 reduction. Acidic and basic hydrolysis of the methyl ester were 
attempted to convert the methyl ester back to acid. However, the yield was 
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extremely low due to the relative instability of 15-HPETE. A chiral AD-RH 
column was applied to separate 15(R,S)-HPETE methyl ester as shown in 
Figure 3.12.In the left LC-UV chromatogram, the peak at 17.2 min 
corresponds to the S form of 15-HPETE-Me, while the peak at 18.2 min 
corresponds to the R form. Figure 3.12(a) shows LC-ESI/MS data of racemic 
15-HPETE methyl ester, while 3.12(b) shows 15(S)-HPETE-Me only, so the 
peak at 10.6 min is 15(R)-HPETE-Me. 
 
Figure 3.12, LC-UV purification and LC-MS confirmation of 15-HPETE 
methyl ester. The reaction mixture was purified by Chiralpak AD-H column 
with mobile phase of hexane/ethanol (100:2), and UV absorption at 236 nm 
was monitored. Figure (a) and (b) are 15-HPETE-Me samples analyzed by 
Chiralpak AD-RH column coupled with LTQ-ESI/MS. The LC-MS conditions are 
shown in the experimental procedures section. 
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3.5 DISCUSSION 
HNE and ONE can be generated from linoleic acid and AA autoxidation in 
vitro. However, in cells the redox potential is strictly regulated, which means 
the free radical induced non-enzymatic autoxidation is very limited and the 
corresponding autoxidation products are at low levels. In contrast, when 
COXs and LOXs are present, linoleic acid or AA can be efficiently converted 
stereoselectively into lipid hydroperoxides in inflammatory cells and in many 
cancer tissues. The major product of COX-2 mediated AA oxidation is PGG2. 
From analysis of HNE-GSH adduct generated from different eicosanoids, it 
was shown that PGG2 could be converted into 4(S)-HNE; whereas, 11(R)-
HPETE, which is the major acyclic lipid hydroperoxide, generated racemic 
4(R,S)-HNE. Furthermore, 15(S)-HPETE, a major product of the 15-LOX/AA 
pathway, was converted into 4(S)-HNE, while 15(R)-HPETE, the major 
product of aspirin-treated COX-2, was converted into 4(R)-HNE. 
Characterization of the different eicosanoid-derived HNE enantiomers made it 
possible to evaluate the individual contributions of these eicosanoid precursor 
and their related pathways to formation of the reactive aldehydes HNE and 
ONE.  Interestingly, 4(S)-HNE was the major form of HNE formed from either 
recombinant COX-mediated AA oxidation in the presence of hematin as well 
as from COX-2 expressed LoVo cell lysate. This result indicates that PGG2 
contributes is the major contributor to the formation of HNE. This means that 
COX-derived ONE, which shares the same precursor as HNE, also arises from 
PGG2. This new finding implies that ONE-mediated DNA damage also arises 
from PGG2 rather than from HPETEs as had been assumed previously (67). 
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The fact that PGG2 is mainly converted into 4(S)-HNE suggests a novel 
decomposition mechanism. It is proposed that the 12-HPTrE formed when 
PGG2 is converted to MDA forms a dihydroperoxide similar to that proposed 
for 5(S)-HPETE (36), which subsequently decomposes to 4(S)-HPNE via a 
Hock rearrangement. Furthermore, it further highlights the need for 
adequate intracellular reducing equivalents to convert PGG2 into PGH2 and so 
prevent the formation of MDA, HPNE, HNE, and ONE. 
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Chapter 4 
Newly identified OUDE as the 15-HPETE and 11(R)-
HPETE decomposition aldehyde  
 
4.1 ABSTRACT 
. HPNE and HPNE-derived HNE and ONE have been characterized previously. 
However, OUDE, which retains a carboxylic acid group from HPETEs has not 
been identified previously. The formation of OUDE from lipid hydroperoxide 
decomposition was shown to occur by comparing LC-MS and NMR 
information to an authentic standard prepared by organic synthesis. Chiral 
LC-MS analysis of oxime derivatives coupled with the use of [13C]-analogs 
was employed in order to provide insight into the mechanism of formation of 
OUDE. An OUDE isomer, which was formed by C8-C9 double bond 
translocation to C9-C10 was also identified. This isomer possesses a reactive 
,unsaturated aldehyde analogous to HNE. It was found that there are two 
distinct pathways for 11(R)-HPETE and 15-HPETE to form OUDE and HPNE, 
based on the different chirality of HPNE generated from these lipid 
hydroperoxides. The findings of carboxylic acid containing aldehydes could be 
highly significant, considering that they could be generated on esterified 
lipids and disrupt the lipid membrane. This is different from HPNE, which 
cannot form an ester bond to membrane lipids. Thus, HPNE or HNE could 
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play quite different roles in regulating biological processes when compared to 
the corresponding carboxylate-containing OUDE isomers. 
4.2 INTRODUCTION 
15-HPETE and 11-HPETE are generated either from autoxidation of AA as 
racemic mixtures, or stereoselectively from enzymatic pathways. COX-2 
converts free AA into 15(S)-HPETE and 11(R)-HPETE, while 15-LOX converts 
free AA or esterified AA into free 15(S)-HPETE or esterified 15(S)-HPETE 
(109). Both non-enzymatic pathways and enzymatic pathways are enhanced 
in cells under oxidative stress such as during inflammation and cancer. It has 
been known for many years that AA oxidation can generate aldehydes 
(110,111). However, previous research has focused primarily on AA-derived 
aldehydic products, which lack the -carboxylate terminus.. Thus, HNE and 
ONE have been widely studied with regards to their mechanism of formation 
(32,96) and their biological effects (97, 101-103, 107-108). However, 
carboxylate containing aldehydes have attracted much less attention with 
respect to either their identification or their biological roles. 
A number of research groups have studied the oxidized phospholipid 
products (OxPLs) that are present on the surface of LDL or apoptotic cells 
and function as potential CD36 ligand (112,113,114). The Hazen group has 
shown that some of these lipid oxidation products have aldehydes at the  
position (115,116). Through this research, a relationship between lipid 
oxidation and immune recognition has evolved, suggesting that oxidized 
lipids play important role in inflammation and that they are involved in the 
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development of atherosclerosis. Some of the OxPLs are pro-atherogenic and 
some are anti-atherogenic (117,118). Thus, the complexity of OxPL activity 
requires additional investigation into the characterization of these lipid 
aldehydes. 
Previously, Jian et al. identified a novel carboxylate-containing aldehyde, 5,8-
dioxo-6(E)-octenoic acid (DOOE), that was formed from 5(S)-HPETE, a 5-
LOX-mediated AA oxidation product (36,119). One difference between 15-
LOX and 5-LOX is that 15-LOX can use esterified AA or lipoprotein as 
substrate, while 5-LOX can only oxidize free arachidonic acid (120). Thus, it 
was considered more worth studying the decomposition of 15-LOX-derived 
15(S)-HPETE into reactive aldehydes. The resulting aldehyde could also 
potentially exist in an esterified form and so would be present on the surface 
of membrane where it could act as a signaling molecule. 
The mechanism of HPETE decomposition to aldehydes is still not 
completely clear, although several groups have proposed some potential 
schemes (as shown in chapter 1). It is extremely challenging to capture the 
reactive intermediates that are precursors of the resulting aldehydes due to 
rapidity of potential radical reactions and the instability of any radical 
intermediates. Thus, we studied the chirality of the final aldehyde product, 4-
hydroxy-nonenal (HPNE) at its C4 position, similar as the method used by 
the Brash Group (see Chapter 3). The chirality of HPNE formed from different 
precursors indicated that there were two distinct decomposition pathways 
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from 15-HPETE and 11(R)-HPETE. Furthermore, the made it possible to 
determine the relative contributions of different HPETEs to HPNE levels. 
 
 
Figure 4.1 Chemical structures of 15-HPETE, 11-HPETE, OUDE1 and 2, 
and OUDE Girard T derivative  
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Figure 4.2. Proposed mechanism for formation of OUDE from 15(S)-
HPETE and 11(R)-HPETE 
4.3 EXPERIMENTAL PROCEDURES 
4.3.1 Chemicals and Reagents. 
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AA, HPNE and [2H3]-4-HNE were purchased from Cayman (Ann Harbor, MI). 
Girard T reagent, hydroxylamine hydrochloride, L-glutathione, L-ascorbic acid, 
and lipoxidase from Glycine max (soybean) were purchased from Sigma-
Aldrich (St. Louis, MO). LC-MS grade water, tert-Butyl methyl ether, 
methanol, isopropanol, acetonitrile and dichloromethane were obtained from 
Fisher Scientific (Pittsburgh, PA). Gases were supplied by The Linde Group 
(Munich, Germany). 
4.3.2 MS conditions. 
For oxime derivatives analysis, the Finnigan LTQ mass spectrometer (Thermo 
Electron, San Jose, CA) was used in the positive ion mode with an ESI source. 
The operating conditions were: spray voltage at 4 kV; capillary temperature 
at 250°C; capillary voltage at 35 V; nitrogen as sheath (40 psi) and auxiliary 
(20 arbitrary units) gas.  CID was performed using helium as the collision gas 
in the ion trap. The following SRM transition (m/z 188 → 154) was monitored 
for HPNE-oxime (normalized CE, 25 %), and SRM transition (m/z 172 → 99) 
was monitored for HNE-oxime (normalized CE, 25%). 
For GSH adduct analysis, the triple stage quadrupole (TSQ Quantum) mass 
spectrometer (Thermo Electron, San Jose, CA) equipped with an ESI source 
was used. TSQ Quantum was operated in the positive ion mode with an ESI 
source. The operating conditions were: spray voltage at 4 kV; capillary 
temperature at 350°C; nitrogen as sheath (35 psi) and auxiliary (13 arbitrary 
units) gas. CID was performed using argon as the collision gas at 1.5 mtorr 
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in the Rf-only quadrupole.  The following SRM transition (m/z 464 → 308) 
was monitored for HNE-GSH (CE, 14 eV). 
For high resolution mass analysis, the Thermo LTQ Orbitrap XL hybrid FTMS 
(Fourier Transform mass spectrometer) equipped with a Michrom nano ESI 
source was used. It was operated in negative mode for free fatty acid 
analysis, while in positive mode for Girard T derivatives analysis. The 
operating conditions were: spray voltage at 1.75kV; capillary temperature at 
250 ˚C; capillary voltage at 49 V; helium as collision gas. For full scan, the 
resolution was set at 30 000. For MS/MS, the isolation width used was 2.5, 
the resolution for the products analysis was 30 000, and the collision energy 
was 35 %. 
4.3.3 LC methods. 
LC separations were conducted using a Waters Alliance 2690 HPLC system 
(Waters Corp., Milford, MA, USA). A Chiralpak AD-RH column (150 × 4.6 mm 
inner diameter, 5 µm; Daicel Chemical Industries, Ltd., Tokyo, Japan) was 
used for reverse phase (isocratic method 1, flow-rate 0.5 ml/min) separation 
of the HNE and HPNE oxime derivatives.  The mobile phase for isocratic 
separations was methanol/water (85:15; v/v) containing 0.1 % formic acid. 
OUDE was purified by preparative LC (Ultrasphere™ 250 × 10 mm, inner 
diameter, 5 µm; Beckman) using Hitachi LC system by monitoring the UV 
absorbance at 236 nm. The mobile phase for isocratic method 2 was 
hexane/isopropanol (97:3; v/v) with 0.1 % acetic acid as the modifier. 
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GSH-adducts were separated by reversed phase using gradient 1 on Waters 
Alliance 2690 HPLC system.  The separation employed a Phenomenex 
Synergi Hydro-RP column (150 × 4.6 mm inner diameters, 5 µm). Solvent A 
was 0.1% aqueous formic acid, and solvent B was 
methanol/acetonitrile/formic acid (50:50:0.1; v/v).  Gradient 1 was as 
follows: 2% B at 0 min, 12% B at 14 min, 30% B at 20 min, 42% B at 21 
min, 65% B at 27 min, 80% B at 29 min, 90% B at 33 min, 90% B at 34 min, 
2% B at 35 min. The flow rate was 0.4 ml/min.  The separation was 
performed at ambient temperature using a linear gradient. 
A Waters nanoAcquity UPLC system was coupled to the LTQ orbitrap XL. The 
column used to separate free fatty acids or Girard T derivatives was a Waters 
Acquity C18 (150 mm × 150 m inner diameter, 1.7 m). Solvent A was 0.1% 
aqueous formic acid, and solvent B was acetonitrile with 0.1% formic acid. 
The flow rate was 2 l/min, and the column temperature was 35 ˚C. 
For fatty acid analysis, gradient 2 was as follows: 35% B at 0 to 6 min, 90% 
B at 8 min, 98%B at 23 min to 26 min, and 35% B at 27 min till 37 min. For 
Girard T derivatives, Gradient 3 was as follows: 10% B from 0 min to 6 min, 
50% B at 8 min, 80% B at 23 min, 98% B from 24 min till 27 min and 10% 
B from 28 min to 38 min. 
4.3.4 NMR method. 
NMR Spectra were determined at ambient temperature on a Bruker Avance 
500 instrument. 1H experiments were carried out at 500 MHz. The samples 
(0.5-0.8 mg) were dissolved into 300 ml CDCl3. The data processing was 
 
 
103 
performed on the spectrometer. Chemical shifts are expressed in parts per 
million (ppm) downfield from the residual solvent peak of 7.26 ppm for CDCl3 
for 1H NMR. Splitting patterns are indicated as follows: br, broad; s, singlet; 
d, doublet; t, triplet; q, quartet; dd, doublet of doublets; dt, doublet of 
triplets. 
4.3.5 GSH derivatization. 
The lipid hydroperoxides decomposition reactions were performed in the 
presence of 4 mM GSH, and then the aldehydes GSH conjugates were formed 
during the incubation at 37 C for 30 min. Then the reaction mixtures were 
loaded to SPE cartridges (HLB, Oasis, 30 mg) which were pre-conditioned by 
adding 1 ml methanol and 1 ml water. After loading samples, the cartridges 
were washed with 1ml water to remove excess GSH, and then 0.5 ml 
methanol was added to elute the analytes. The elutent was directly analyzed 
by LC-ESI/SRM/MS or concentrated under N2 flow. 
4.3.6 Girard T derivatization. 
Aldehydes in 200 l buffer (100 mM MOPS, 150 mM NaCl, pH7.2) were added 
with 10 l acetic acid and 1 mg Girard T reagent. The reaction mixture was 
kept at room temperature for 30 min and then transferred to SPE cartridge 
(HLB, Oasis, 30mg) pre-conditioned with 1 ml methanol and 1 ml water. The 
cartridge was then washed with 1 ml water, and then 0.5 ml methanol added 
to elute analyte. The elutent was evaporated to dryness in N2 flow, and 
dissolved in 100 µl of water/acetonitrile (95:5; v/v). The solution was then 
transferred to Costar Spin-X nylon centrifuge filter (0.22 m), and 
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centrifuged at 10 000 x g for 5 min. Then the clear solution was analyzed by 
nano UPLC-ESI/MS. 
4.3.7 Preparation of OUDE. 
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Figure 4.3 Synthesis of OUDE1 and OUDE2. 
Methyl 11-(tetrahydro-2H-pyran-2-yloxy)undeca-5,8-diynoate (5). Methyl 
hex-5-ynoate 4 (2.76 g, 21.85 mmol) was added to a mixture of K2CO3 (5.03 
g, 36.40 mmol), CuI (4.51 g, 23.67 mmol) and NaI (5.46, 36.40 mmol). The 
mixture was stirred for 30 min and 3 (139) was added. The reaction was 
stirred for 16 hrs. Ether (200ml) was added and washed with saturated NH4Cl 
solution, water and brine. The solvent was evaporated for chromatography 
(10% EtOAc in Hexanes) to supply 5 (3.24 g, 61%). δH (500 MHz, CDCl3) 
3.92-3.67(m, 5H), 3.35 (s, 3H), 2.53-2.38 (m, 8H), 2.24-2.22 (m, 4H), 
1.83-1.81 (m, 4H). 
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(5Z,8Z)-Methyl 11-(tetrahydro-2H-pyran-2-yloxy)undeca-5,8-dienoate (6). 
NiOAc.4H2O (0.68 g, 2.73 mmol) was dissolved in MeOH (20 mL) and the 
flask was flashed with H2 three times. NaBH4 (75 mg, 1.98 mmol) in NaOH (8 
mL, 0.2 M) was added in one portion. After gas evolution had subsided, 0.8 
mL of ethylenediamine was added and the mixture was stirred for 5 min. A 
(1.60 g 5.48 mmol) in methanol (2 mL) was added and the hydrogenation 
was continued for 4 hrs. The mixture was filtrated and the solvent was 
evaporated. The residue was taken up with EtOAc and washed with water. 
The organic layer was evaporated for flash chromatography (10% EtOAc in 
Hexanes) to provide 6 (1.0 g, 62%). δH (500 MHz, CDCl3) 5.42-5.35(m, 4H), 
4.59-4.58 (m, 1H), 3.87-3.83 (m, 1H), 3.75-3.70 (m, 1H), 3.65 (s, 3H), 
3.50-3.47 (m, 1H), 3.42-3.37 (m, 1H), 2.79-2.77 (m, 2H), 2.36-2.29 (m, 
4H), 2.10-2.07 (m, 2H), 1.82-1.69 (m, 8H). 
(5Z,8Z)-Methyl 11-hydroxyundeca-5,8-dienoate (7). PTSA.H2O (1.83 g, 9.62 
mmol) was added to a solution of 6 (0.95 g, 3.21 mmol) in methanol (20 mL) 
and stirred overnight.  20 mL sat. NaHCO3 was added to the mixture and 
methanol was evaporated.   The mixture was then extracted with EtOAc and 
washed with brine. The organic layer was evaporated for flash 
chromatography (20% EtOAc in Hexanes) to provide 7 (558 mg, 82%). δH 
(500 MHz, CDCl3) 5.50-5.46 (m, 1H), 5.40-5.33 (m, 3H), 3.64-3.61 (m, 5H), 
2.79-2.77 (m, 2H), 2.33-2.29 (m, 4H), 2.09-2.04 (m, 3H), 1.69-1.66 (m, 
2H). 
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(5Z,8Z)-Methyl 11-oxoundeca-5,8-dienoate (8). Dess-Martin reagent (2.00 g, 
4.71 mmol) was added to a solution of 7 in DCM (20 mL) and stirred for 2 
hrs. Sat. NaHCO3 (20 mL) was added to the mixture and the mixture was 
extracted with DCM. The organic layer was evaporated for flash 
chromatography (20% EtOAc in Hexanes) to supply 8 (490 mg, 99%). δH 
(500 MHz, CDCl3) 9.66 (s, 1H), 5.65-5.49 (m, 4H), 3.66 (s, 3H), 2.33-2.319 
(m, 5H), 2.16-2.09 (m, 1H), 1.69-1.66 (m, 4H). 
(5Z,8Z)-Methyl 11,11-dimethoxyundeca-5,8-dienoate (9). 
Trimethylorthoformate (227 mg, 2.41 mmol) was added to a solution of 8 
(50 mg, 0.238 mmol) and CeCl3.7H2O (92 mg, 0.25 mmol) in MeOH (10 mL) 
and stirred for 2 hrs.  10 mL sat. NaHCO3 was added to the mixture and the 
mixture was extracted with EtOAc. The organic layer was evaporated for 
flash chromatography (10% EtOAc in Hexanes) to provide 9 (40 mg, 66%). 
δH (500 MHz, CDCl3) 5.49-5.36 (m, 4H), 4.39-4.38 (m, 1H), 3.67 (s, 3H), 
3.33 (s, 6H), 2.79 (bs, 1H), 2.41-2.30 (m, 4H), 2.17-2.05 (m, 1H), 1.70-
1.67 (m, 4H). 
(5Z,8Z)-11-Oxoundeca-5,8-dienoic acid (10) and (5Z,9E)-11-oxoundeca-5,9-
dienoic acid (11). 3N LiOH (2mL, 6 mmol) was added to a solution of 9 (40 
mg, 0.156 mmol) in THF (5mL) and stirred for 2 hrs at 60 °C.  The mixture 
was extracted with EtOAc after acidification with 3N HCl. The organic layer 
was evaporated for flash chromatography (EtOAc) to provide the crude acid 
(30 mg, 79%). 
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3N HCl (1 mL, 6 mmol) was added to the above crude acid in ACN (5 mL) 
and stirred for 2 hrs at r.t. The mixture was extracted with EtOAc. The 
organic layer was evaporated for HPLC (Beckman, Ultrasphere, 250x10 mm, 
UV: 236 nm, Hexane/isopropanol/acetic acid = 97:3:0.1, 2.5 mL/min, 
isocratic method 2). 
4.3.8 Lipid hydroperoxides decomposition in the presence of Vit C or 
iron.  
15(S)-HPETE (5 µg) in 200 µl Chelex-treated 100 mM MOPS buffer (pH 7.2), 
containing 150 mM NaCl was incubated with 1 mM Vit C at 37 °C for 24 hr. 
Ethyl acetate (2×800 µl) was added to extract products. The organic layer 
was evaporated and dissolved to 100 µl MeOH/H2O (4:6, v/v). The solution 
was filtered by Costar nylon 0.22 m filter and 2 µl of each sample was 
injected to UPLC-ESI-LTQ Orbitrap/MS (gradient 3). For GT derivatives, the 
method was described previously in section 4.3.6. 
4.3.9 Chirality character of HPNE-oxime derivative formed from 
hydroperoxides.  
HPETEs (300 µM) were incubated at 37 ºC with 2 mM Vit C in 200 µl Chelex-
treated MOPS buffer (100 mM, pH 7.2), containing 150 mM NaCl. After 1 h, 1 
mg hydroxylamine hydrochloride was added to the reaction mixture and the 
incubation was continued for 1 h before extraction with diethyl ether (2 X 
600 µl). Ethyl layer was evaporated in N2. Samples were dissolved into 100 
µl MeOH/water (85:15; v/v), and 20 µl was injected to LTQ-ESI/SRM/MS 
(isocratic method1). 
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4.3.10 Characterization of epoxide alcohol formed from 15(S)-HPETE. 
To confirm the formation of epoxide alcohol from 15-HPETE, the reaction 
mixture was first purified by MTBE and then the organic phase was 
evaporated and re-dissolved into 200 l acetonitrile containing 0.1 N HCl. 
Here acetonitrile instead of buffer was used to prevent water competing with 
chloride ion to attach to the epoxide. The mixture was kept for 30 min at 
room temperature, and then diluted 10 times before analyzed by nanoUPLC-
LTQ orbitrap-ESI/MS. 
 
4.4 RESULTS 
4.4.1 Preparation and confirmation of OUDE. 
OUDE was chemically synthesized as described above. When the reaction 
mixtures were purified using Hitachi a semi-preparative LC-UV system, two 
peaks collected, which shared the same molecular weight, the same 
retention time on UPLC C18 column and even the same MS/MS 
fragmentation when they were detected by the LTQ-Orbitrap (Figure 4.4) 
Thus, they were named OUDE as OUDE1 and 2, depending on the elution 
order from semi-preparative column. OUDE1 had a retention time of 13.4 
min, while OUDE2 was eluted at 16.4 min. 
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Figure 4.4. LC-orbitrap/MS/MS data of synthetic OUDE and its isomer. 
The top channels are corresponding the retention of OUDE1 and 2 on C18 
column, while the lower spectrum show the MS/MS fragmentation of OUDE1 
and 2 at collision energy 35%. 
 
NMR was performed for these two isomers (Figure 4.5). For OUDE1: δH (500 
MHz, CDCl3) 9.68 (s, 1H), 5.69-5.40 (m, 4H), 2.80-2.78 (m, 2H), 2.44-2.32 
(m, 2H), 2.15-2.02 (m, 2H), 1.73-1.61 (m, 4H). For OUDE2: δH (500 MHz, 
CDCl3) 9.50 (d, J = 8.0 Hz, 1H, H-11), 6.85 (dt, J = 15.5, 8.0Hz, 1H, H-9), 
6.15 (dd, J = 15.5, 8.0Hz, 1H, H-10), 5.43-5.37 (m, 2H), 2.79-2.73 (m, 2H), 
2.42-2.24 (m, 4H), 1.73-1.64 (m, 4H). The insert in the OUDE2 NMR 
spectrum is the enlarged chemical shift range from 5.5 to 7 ppm. The 
doublet of triplets peak splitting pattern of H9 and the doublet of doublets 
pattern of H10 indicate the C9-C10 double bond, and also indicate C10 is the 
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one close to the terminal aldehyde. These patterns were not observed in 
OUDE1, so OUDE2 is the C8-C9 double bond translocation of OUDE1. 
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Figure 4.5. The NMR spectra of OUDE1 and OUDE2 at 500 MHZ. 
4.4.2 Lipid hydroperoxides decomposition in the presence of Vit C or 
iron. 
15-HPETE and 11(R)-HPETE underwent decomposition in the presence of Vit 
C or iron, and the decomposition products were analyzed by reverse phase 
LC coupled with high resolution orbitrap MS in the negative mode (Figure 
4.6). To increase the detection sensitivity, the aldehydes products were 
converted to Girard T derivatives (Figure 4.7). [13C20]-11(R)-HPETE was 
synthesized from [13C20]-AA by 11-LOX enzyme (a kind gift from Dr. Alan 
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Brash, Vanderbilt University). The reaction conditions and purification 
conditions were same as for unlabeled 11(R)-HPETE or 15(S)-HPETE. Figure 
4.7(g) shows a mass spectrum of the [13C11]-OUDE GT derivative derived 
from [13C20]-11(R)-HPETE decomposition, Figures 4.7(d) to 4.7(f) shows the 
product ions from the MS/MS analysis of OUDE GT at collision energy of 35%, 
while the lower mass spectrum shows the product ions from [13C11]-OUDE GT 
at same collision energy. It is clear that the product ions observed in Figure 
4.7(g) mass spectrum have an 11 Da mass shift when compared to the 
product ions in Figures 4.7(d) to 4.7(f). This not only indicates that OUDE 
contains eleven carbons, but also indicates that these ions arise from 
cleavage of a Girard T moiety. 
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Figure 4.6. LC-MS detection of OUDE from 15(S)-HPETE and 11(R)-
HPETE. 
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Figure 4.7. LC-MS/MS of OUDE-GT derivative and [13C11]-OUDE-GT 
derivative. 
 
However, based on this evidence alone it remains unknown whether OUDE1 
or OUDE2 is formed from HPETE decomposition, since these two isomers and 
their GT derivatives have the same elemental compositions, similar retention 
times, and also MS/MS fragments. Thus, OUDE was conjugated with 
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hydroxylamine to make the oxime derivative (to increase MS response by 
introducing a nitrogen atom) and then Chiralpak AD-RH column was applied 
to separate these isomers. Both OUDE1 and OUDE2-oxime were split into 
two peaks, which corresponded to syn- and anti-isomers, due to the newly 
formed C=N double bond. Figure 5, clearly shows that OUDE1-oxime and 
OUDE2-oxime are well separated on the AD-RH column. From this Figure, it 
is also evident that 15(S)-HPETE-derived OUDE is a mixture of OUDE1 and 
OUDE2 isomers. 
 
Figure 4.8. Chiral LC-MS detection of OUDE-oxime derivative from 
15(S)-HPETE and authentic OUDE. (a) shows OUDE-oxime from 15(S)-
HPETE decomposition, (b) shows authentic OUDE-oxime, while (c) shows 
OUDE-oxime with double bond translocation. 
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4.4.3 Chirality of HPNE-oxime derivatives formed from eicosanoids. 
In order to determine a potential decomposition mechanism, HPNEs 
generated from HPETE decomposition were converted to oxime derivatives 
and separated on AD-RH column. In Figure 4.9, it is evident that HPNE 
derived from 15-HPETE retains the original chirality at C-15 position, while 
HPNE from 11(R)-HPETE was a racemic 1 to 1 mixture.  Thus, it is proposed 
that the 15-hydroperoxy group in 15-HPETE does not participate in the 
decomposition of HPETE to HPNE. In contrast, it appears that for 11(R)-
HPETE, a beta scission occurs at C-11 (Figure 4.1). 
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Figure 4.9. The chiral characters of HPNE formed from HPETEs. 
Figures a to d show the chromatography of HPNE hydroxylamine derivative 
(HPNE-oxime) formed from 11(R)-HPETE, 15(S)-HPETE, 15(S)-HPETE methyl 
ester and 15(R)-HPETE methyl ester, respectively. Figure (e) is the 
chromatography of racemic HPNE-oxime standard. HPNE-oxime is separated 
by reverse phase LC, and monitored by SRM transition m/z 188 to 154. 
 
4.4.4 Characterization of epoxide alcohol formed from 15(S)-HPETE. 
To confirm the hypothesis that an epoxide alcohol was a major intermediate, 
the 15(S)-HPETE reaction mixture was incubated with 0.1 N HCl, and the 
products were analyzed by LC-MS (Figure 4.10). The relative intensity ratio 
of 371.1995 to its highest isotope peak 373.1965 is 3 to 1, which agrees with 
the predicted ratio. This isotope distribution pattern confirms the presence of 
Cl and indicates the original compound contained an epoxide group. Figure 
4.10(d) shows the MS3 product ion spectrum from the MS2 product ion, 
317.2121, which is an HCl elimination product. The ion at m/z 193.1235 was 
generated through cleavage between C12 and C13, while the ion at m/z 
235.1340 was formed by cleavage between C14 and C15, together with loss 
of a water molecule (Figure 4.10 d).  
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Figure 4.10. Hydrolysis of epoxide in the presence of 0.1 N HCl. Figure, 
(a) is the reconstructed ion of 371.1995 with 3 ppm window. The product ion 
spectrum of this peak is shown in (c), where 371.1995 indicates the mass 
assignment was correct to the fourth decimal place.  The ion at m/z 
373.1965 corresponded to the 37Cl isotopomer. The lower channel (d) shows 
the MS3 product ions derived from the ion at m/z 371.1995. 
 
4.5 DISCUSSION: 
The novel aldehyde OUDE was identified as a product from the non-
enzymatic decomposition of 15-HPETE and 11(R)-HPETE. Two OUDE isomers 
were identified.  OUDE2 contains an ,–unsaturated aldehyde and so can be 
considered to be a carboxylate-containing analog of ONE. These two OUDE 
isomers differ by the location of C9-C10 double bond, so they or their GT 
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derivatives cannot be distinguished simply by LC-MS analysis. However, they 
show different NMR spectra and different retention times on Chiral AD-RH 
column. Although the driving force for the double bond translocation is 
unknown, both isomers were observed in the decomposition of 15- and 11-
HPETE. This phenomenon also indicates the complexity of the products that 
can arise from lipid oxidation. The bis-allylic hydrogen atoms that are present 
in AA can be readily replaced by molecular oxygen while the number of 
double bonds contributes to the formation of complex structural isomers. 
15-HPETE is the primary product of 15-LOX, and numerous studies have 
shown that 15-LOX is involved in oxidized LDL formation. This is based on 
the evidence that there is co-localization of 15-LOX and oxidized LDL (122, 
123). It is not completely clear how 15-LOX contributes to LDL oxidation. 
There are several potential explanations. First, although 15-LOX is a cytosolic 
enzyme, it might be excreted out of cells when cells are under injured 
conditions. Once the LDL membrane is oxidized by 15-LOX, changing of 
hydrophobicity would cause a re-alignment of the original membranes. The 
oxidized moiety would flip up and be present on the membrane surface, 
where it could be recognized by the CD36 receptor (113). Second, oxidized 
LDL could be taken up by macrophage cells, and since LDL is rich in 
unsaturated fatty acids, such as linoleic acid and AA, which could be 
substrates for 15-LOX-mediated oxidation for further oxidation. There is 
evidence showing 15-LOX is active in the presence of lipid drops (124). Third, 
the lipids oxidized by 15-LOX might be released from cells and be recruited 
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by LDL. It was reported that oxidized fatty acids could be incorporated into 
membranes and play important biological roles (125,126, 127). 
11-Oxo-ETE is rapidly excreted from LoVo cells (chapter 2), and so it is 
possible that there are also an export transporters for other oxidized lipids. 
Yoshimoto and colleagues suggested a potential mechanism, which involved 
the exchanging of cholesteryl esters of LDL with cell membranes and the 
relocation of 15-LOX to the LDL binding site (128). 11(R)-HPETE is the major 
product from the LOX-like activity of COX. Since the substrate of COX has to 
be free fatty acids, then it is less likely that COX will directly oxidize LDL. 
However, COX will generate free OUDE1 and OUDE2, which could be secreted 
and transported to other cells or LDL. 
In summary, there is substantial evidence suggesting a relationship between 
oxidized lipids and immune recognition. The studies described above have 
shown that 15-LOX and COXs can contribute to the formation of oxidized 
lipids with structural similarity to immunogenic lipids. This provides a 
potential novel pathway by which lipids could be involved in immune 
recognition. 
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Chapter 5 
Conclusion and future directions 
 
5.1 Conclusions 
COX-2 converts AA into PGG2, 11(R)-HPETE, 15(S)-HPETE and 15(R)-HPETE 
(Chapter 3). Although there are intense studies showing that COX-2 
contributes to cancer development by generating PGE2, which is pro-
inflammatory and oncogenic, the studies described above have revealed that 
the PGG2 and the HPETEs can decompose to shorter chain aldehydes HNE 
and ONE, which could be involved in a myriad of biological processes 
(Chapter 3). 11(R)-HPETE was found to generate a racemic mixture of 
4(R,S)-HNE, while PGG2 and 15(S)-HPETE generated only 4(S)-HNE and 
15(R)-HPETE generated only 4(R)-HNE. HNE and ONE can cause oxidative 
stress by GSH depletion, or alternatively, they can modify proteins and DNA, 
resulting in the dysregulation of protein function or causing DNA mutations. 
4(S)-HNE was the major enantiomer identified in COX-2-expressiong LoVo 
cells, suggesting that its major source was it’s the initially formed COX-
derived product of AA oxidation, PGG2. Earlier studies have shown that HNE 
can be derived from HPNE, which also serves as the precursor to ONE. This 
suggests that any COX-2-derived ONE also arose from PGG2 decomposition 
rather than the HPETEs as had been previously suggested. No ONE dGuo 
adduct (H-dGuo) was found in COX-2 expressing LoVo cells, suggesting that 
DNA repair was more efficient than in rodent epithelial cells or that the ONE 
was detoxified more rapidly. Therefore, additional human cell lines should be 
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examined to determine whether H-dGuo can be detected. If human cells do 
have advanced DNA repair system the excised DNA-adduct may be present 
in urine, which would be a good biomarker for exposure to COX-2-mediated 
DNA-adduct formation. 15-HPETE and 11(R)-HPETE also generate the 
carboxylate-containing aldehydes, OUDE 1 and 2, which might be 
incorporated into membranes and function as signaling molecules, for 
example, the ligand of CD36 receptor (Chapter 4). Thus, not only 15-LOX is 
related to OxPLs formation, but also COX-2. There are many enzymes 
involved in the conversion of COX-2-derived AA metabolites into other 
eicosanoids. The ability of 15-PGDH to oxidize 11(R)-HETE into 11-oxo-ETE 
was clearly demonstrated. The resulting 11-oxo-ETE I rapidly secreted from 
cells presumably by the action of membrane transporters, or is further 
transformed by GST/GSH or unknown reductases (Chapter 2). 11-Oxo-ETE 
might play an important role in inhibiting endothelial cell proliferation. 
Additional studies will be required in order to elucidate the anti-proliferative 
effect of 11-oxo-ETE. Considering the structural similarity of 11-oxo-ETE to 
other oxidized lipid products, it might either bind to PPARand activate PPAR 
regulated gene transcription or bind the cysteine residue of the NF-B DNA 
binding domain and inhibit NF-B activity. Such future mechanistic studies 
would further our understanding of how the COX-2/15-PGDH pathway is 
involved in the regulation of tumorogenesis. Clearly, the physiological levels 
of these AA metabolites are controlled by multiple pathways, and the 
changing of any of these pathways would cause a shift in the eicosanoid 
levels, and initiate a series of biological consequences. The studies described 
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above have provided additional insight into how such changes could impact 
on pathophysiological processes. 
LC-MS techniques were critical for the studies on AA metabolites, because of 
the high sensitivity and specificity that could be obtained when compared 
with other techniques, such as LC-UV or LC-NMR. Moreover, it was possible 
to analyze a broad spectrum of metabolites because they did not have to 
possess UV activity. Most of the metabolites could be analyzed by LC-MS, 
chemical derivatization was used in some cases to increase the MS response. 
Specific examples of derivatives that were used included PFB, GT, and 
oximes (Chapters 2 and 3). Moreover, LC coupled with high resolution MS 
further increased the detection specificity, since most high resolution MS 
(HRMS) can give mass accuracy to the third or fourth decimal place (Chapter 
4), which facilitated the determination of a compounds elemental 
composition and structure elucidation. In addition, another advantage of LC-
MS is that it could analyze crude samples with minimal sample purification 
procedures, although a de-salting process (SPE method) was required in 
order to avoid complex adduct formation between the analyte and different 
cations such as sodium, potassium or ammonium.  
5.2 Future directions 
Considering the complexity of AA metabolism, the major limit of current 
methodology is that it focuses on limited numbers of metabolites within a 
specific cell line. Therefore, it is difficult to conclude whether these targets 
are the major metabolites and decide which ones are undergoing the most 
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significant changes when comparisons are made between different 
treatments. The growth of metabolism software and metabolite databases, 
together with HRMS, will make it possible to begin addressing these issues 
(129, 130). Newly launched mass spectrometry platforms, such as LTQ-
Orbitrap, TripleTOF 5600, and Q-exactive, all provide high resolution capacity, 
which facilitate good mass accuracy (131, 132, 133). The data from different 
cell treatments or from different population after analyzed by HRMS can be 
loaded to a software package such as XCMS or SIEVE in order to determine 
the most significant changes. Initially the software aligns the chromatograms 
and then and after alignment of the LC chromatography, the software will 
extract peaks based on retention time and m/z. It will then provide the 
relative levels of different metabolites initially identified by comparing m/z 
information to the existing database, such as Metlin, chemical spider, and 
lipidmaps (134, 135, 136). However, the small molecule metabolite 
databases are far from completion, and compared to proteomic databases, it 
is more complex to assign specific structure. This is due to the enormous 
diversity of structures that can be encountered with small molecule 
metabolites (<1500 Da). Thus, more basic discovery research will be 
required in order to make the databases more complete.  
The analysis of small molecule metabolites based on HRMS is rarely enough 
to provide accurate quantitation and complete specificity, since no single tool 
is currently available is applicable to every experimental design. Besides LC-
MS, NMR is also crucial for unknown metabolite structure elucidation. The 
characterization of OUDE isomers in chapter 4 is a good example. However, 
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NMR does have a major limitation it lacks the sensitivity to analyze trace 
amounts of metabolites.  
Gene and protein expression changes will modulate metabolite levels, and in 
complex feedback relationships, fine tuning of metabolites will also affect 
genes and proteins through direct modifications or multiple-step signal 
transductions. Mapping the interaction between metabolic genes, enzymes, 
and small molecule metabolites is the ultimate goal of metabolism study. The 
combination of genomics, proteomics, and metabolomics tools will help to 
understand the multiple layers of regulatory mechanisms governing cellular 
signaling, and will also help to uncover more disease related pathways or 
targets (137, 138, 139). As described in chapter 1, aspirin is an important 
drug, not only because of its anti-inflammatory effect, but also because its 
potential anti-cancer benefit. It is well know that aspirin inhibit PG formation 
through acetylation of COX-1 and COX-2. It is believed that there are other 
possible pathways, other than inhibition of PGs, which are also regulated by 
aspirin to inhibit cancer development (140-142). The acetylation of other 
proteins or enzymes by aspirin might affect the formation of other 
metabolites.. Ultra performance liquid chromatography (UPLC) coupled with 
high resolution MS will facilitate the analysis of such metabolites in an 
accurate yet efficient way, which will be highly complementary to the 
proteomics analysis of acetylated proteins. 
In addtion, considering the incredible complexity of biological system, the 
variations of metabolite biosynthesis will also depend on the cell types or 
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tissues, as well as the species being studies. Thus, simple comparison of two 
samples in one dimension of biological complexity is less meaningful without 
taking other biological variations into consideration. To draw a picture of 
metabolites level in different tissues or species or human subjects will require 
the teamwork from different research groups. A recently published integrated 
colon cancer genomic study is a good example showing large variations from 
different sample types and the teamwork enables the researchers get the 
genomics information from different types of colon cancer (143). By systemic 
study, it was possible to identify the most frequent gene mutations from 
different tumors. This information can also provide important guidance for 
the analysis of small molecule metabolites from colon cancer, as they 
highlight certain pathways for further study. However, the factors causing 
DNA mutations are not well-understood yet. Thus, our findings of new 
bioactive aldehydes generated from COX-2 might contribute to DNA damage, 
even though it has not been yet been possible to fully evaluate the 
importance of COX-2-derived AA metabolism. Therefore, it might be worth 
building a database for DNA adducts, so that different research groups could 
develop screening methods for DNA-adduct detection from different types of 
samples. In this way, it would be possible to connect the major DNA adducts 
to sample types, which would in turn would provide a better understanding of 
the relationship between the pathways causing DNA-adduct formation and 
the resulting DNA mutations. This would ultimately provide better targets for 
chemoprevention based on specific sample types.  
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